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ABSTRACT 
Jennifer Marie Rodenberg 
 
REGULATION OF SRF ACTIVITY BY THE ATP-DEPENDENT CHROMATIN 
REMODELING ENZYME, CHD8 
 
 Under normal conditions, smooth muscle cells do not replicate, or 
proliferate, and provide a means of contraction for many internal organs, 
including blood vessels and the gut. However, under abnormal or disease 
conditions, such as congenital heart disease and cancer, smooth muscle cells 
acquire the ability to replicate, to make extracellular matrix proteins and to 
migrate. Thus, determining how smooth muscle cells regulate these processes is 
crucial to understanding how the cells can switch between normal and diseased 
states. Serum response factor (SRF) is a widely expressed protein that plays a 
key role in the regulation of smooth muscle differentiation, proliferation and 
migration. It is generally accepted that one way that SRF can distinguish 
between these functions is through pathway-specific co-factor interactions. A 
novel SRF co-factor, chromodomain helicase DNA binding protein 8 (CHD8), 
was originally isolated from a yeast two-hybrid assay. CHD8 is widely expressed 
in adult tissues including smooth muscle. Data from in vitro binding assays 
indicate that the N-terminus of CHD8 can interact directly with the MADS domain 
of SRF. Co-immunoprecipitation assays verified the ability of these two proteins 
to interact within cells. Adenoviral-mediated shRNA knockdown of CHD8 in 
smooth muscle cells resulted in statistically significant 10-20% attenuation of 
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expression of SRF-dependent, smooth muscle-specific genes. Similar 
experiments revealed that knockdown of CHD8 did not affect the SRF-dependent 
induction of immediate early genes required to promote proliferation. In contrast, 
knockdown of CHD8 in A10 vascular smooth muscle cells resulted in a marked 
induction in of apoptosis, characterized by increases in apoptotic markers such 
as phospho-H2A.X, cleaved PARP and activated caspase-3. These data suggest 
that CHD8 may play a specific role in modulating SRF’s activity toward anti-
apoptotic genes, thereby regulating smooth muscle cell survival. 
 
B. Paul Herring, Ph.D., chair 
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CHAPTER I 
Introduction 
 
A.  Regulation of Smooth Muscle Differentiation 
 
 i.  Overview of Smooth Muscle 
 
 Smooth muscle cells surround the walls of the body’s hollow organs such 
as the blood vessels, the gastrointestinal tract, the genitourinary tracts, and the 
airways. As a tissue system, smooth muscle provides the contractile force to 
regulate flow of materials through the hollow organs. For instance, in the blood 
vessels smooth muscle contraction and relaxation helps to regulate both the 
blood flow and the blood pressure.  Smooth muscle in the gastrointestinal tract is 
important for regulating the movement of a food bolus for excretion.  Similarly, 
smooth muscle that lines the bladder and urinary tract plays a vital role in the 
expulsion of urine.  The female reproductive tract, where smooth muscle allows 
for the contraction and relaxation of the uterus during both menstruation and 
childbirth, provides another example of the important function of smooth muscle.  
Finally, smooth muscle is critical for the function of the airways, where it helps to 
regulate the intake and expulsion of air. 
 Smooth muscle on the cellular level is extremely complex.  The 
differentiated smooth muscle cell contains a network of contractile and regulatory 
proteins, such as actin and myosin (Owens, 2007).  Smooth muscle cells are 
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spindle shaped, and under normal conditions the smooth muscle cell is largely 
quiescent.  However, this differentiated smooth muscle cell has the uncanny 
ability to change from this quiescent, contractile phenotype under normal 
conditions into a more proliferative, migratory and synthetic phenotype under 
pathological or wound-healing conditions.  This pathological state is often termed 
“de-differentiated,” as cells lose their spindle shape, have multiple protrusions 
and down-regulate expression of many contractile proteins (Owens, 2007). 
 
 ii.  Overview of Smooth Muscle Differentiation 
 
 During mammalian development, or embryogenesis, embryonic stem cells 
give rise to all of the body’s tissues and cells.  One of the main processes of 
embryogenesis is gastrulation, during which cells form the three main germ 
layers of the ectoderm, the mesoderm and the endoderm. The ectoderm is the 
outermost layer, the mesoderm is the middle layer, and the endoderm in the 
innermost layer.  As gastrulation and development continue, the multi-potential 
cells in the embryo begin to move in various directions and manners to form 
different organ systems in the body (Leptin, 2005).  As a general rule, the 
ectoderm forms the nervous system, the sense organs, the skin (epidermis) and 
associated structures and the pituitary gland (Solomon, 1993).  Systems such as 
the skeleton (bone and cartilage), the muscles (skeletal, smooth and cardiac), 
the circulatory system, the excretory system, the reproductive system, the inner 
layer of the skin (dermis), the outer layers of the digestive system and the 
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respiratory system are all derived from the mesoderm germ layer (Solomon, 
1993). The lining of the digestive tract and the respiratory system arise from the 
endoderm.  Thus, much of the body’s smooth muscle is developed from the 
mesoderm, while a small amount is also derived from the endoderm.   
 Looking more closely at the development of the vascular smooth muscle, 
three main origins of vascular smooth muscle cells become apparent:  (a) the 
cranial neural crest population, (b) the proepicardium population and (c) the 
endothelial progenitor cell population (Hirschi and Majesky, 2004).  During 
embryogenesis, bone morphogenetic protein (BMP) signaling creates a gradient, 
allowing for the formation of the neural crest at the mediolateral border between 
the neural plate and the epidermis (Hirschi and Majesky, 2004).  These cells then 
give rise to various types of cells, including smooth muscle cells.  More 
specifically, the cranial neural crest cells, located anterior to somite 5, give rise to 
the vascular smooth muscle cells of the aortic arch arteries, the pulmonary artery 
and the ductus arteriosus (Hirschi and Majesky, 2004). 
 Whereas the cranial neural crest gives rise to the smooth muscle cells of 
the aortic arch and pulmonary artery, the stem cells of the proepicardial organ 
(PEO) differentiate into the smooth muscle cells of the coronary vessels (Hirschi 
and Majesky, 2004).  The PEO structure is transient and establishes contact with 
the heart, which leads to epicardial layer formation (Hirschi and Majesky, 2004).  
Furthermore, cells in this population undergo the epithelial-to-mesenchymal 
transition in response to signals that are released from the myocardium (Hirschi 
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and Majesky, 2004), thereby allowing them to become migratory and to form the 
precursors of the smooth muscle cells in the coronary vessels.   
 The final group of stem cells from which smooth muscle cells are derived 
is the endothelial progenitor cell subset.  Studies have illustrated that depending 
on the conditions present in the environment, these stem cells can form either 
endothelial cells or smooth muscle cells.  More specifically, smooth muscle cells 
are derived from this population in the presence of PDGF-BB (Hirschi and 
Majesky, 2004; Yamashita et al., 2000). 
 In the adult, much of the remodeling and formation of blood vessels has 
been thought to occur from the proliferation and migration of smooth muscle cells 
that are already present.  However, recent studies have suggested that adults 
can differentiate smooth muscle cells from various populations (Yamashita et al., 
2000):  (a) bone marrow-derived stem cells, (b) hematopoietic stem cells and (c) 
circulating stem cells.  The bone marrow has been thought to harbor both 
hematopoietic stem cells and mesenchymal stem cells.  Yet, recently it has been 
illustrated that the bone marrow might also contain a population of vascular 
smooth muscle progenitor cells (Yamashita et al., 2000).  As for the 
hematopoietic stem cells, studies show contradictory results as to whether this 
population contributes to vascular smooth muscle regeneration after injury (Sata 
et al., 2002), or whether this population contributes to the regeneration of 
endothelial cells post-injury (Goodell et al., 1996; Hirschi and Majesky, 2004; 
Jackson et al., 2001).  In addition, various studies have demonstrated that 
progenitor cells within the mononuclear fraction of the blood have the potential to 
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give rise to smooth muscle cells, wherein each group was able to show evidence 
of smooth muscle alpha actin (SM-α-actin) expression from cultured cells 
fractionated from blood (Hillebrands et al., 2001; Hirschi and Majesky, 2004; 
Simper et al., 2002). 
 In general, cellular differentiation can be defined as the process during 
development where multi-potential cells acquire the cell-specific attributes that 
discriminate them from other cell types (Owens et al., 2004).  As Owens, et al., 
describes the actual process of cellular differentiation can be divided into three 
main components:  (a) activation of specific genes that are required for 
differentiation of a cell, (b) control of expression of these specific genes at certain 
times and quantities and (c) regulation of overall gene expression via the 
microenvironmental signals that regulate the cell’s lineage, which includes 
transcription factors and epigenetics (Owens et al., 2004). 
 In the case of smooth muscle cells, a differentiated smooth muscle cell 
can be identified by the expression of specific genes, or smooth muscle markers.  
These markers include:  smooth muscle alpha and gamma actin (SM-α-actin and 
SM-γ-actin), smooth muscle myosin heavy chain (SM-MHC), telokin, SM22α, 
calponin, caldesmon, metavinculin, smoothelin and 130 kD myosin light chain 
kinase (MLCK).  One important characteristic of the promoters of most of these 
smooth muscle marker genes is that they contain at least one CArG element, 
which is the consensus sequence for the transcription factor serum response 
factor (SRF).  However, many other factors also play a role in the regulation of 
these smooth muscle markers as detailed below. 
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  iii.  Mechanisms of Smooth Muscle Differentiation 
 
 Much is still to be elucidated about how smooth muscle cells differentiate 
from the multi-potential cells throughout development.  However, several studies 
have investigated this differentiation phenomenon, and various factors and 
pathways have been described as being involved in the process of deriving a 
smooth muscle cell.  One well-described example of a factor and its signaling 
pathways being implicated in smooth muscle cell differentiation is transforming 
growth factor β1 (TGFβ1). 
 TGFβ1 is a cytokine that signals through multiple membrane receptors 
and intracellular pathways.  Knockout models of either TGFβ1, TGFβ type II 
receptor, activin receptor-like kinase 1 (Alk1), endogelin or SMAD5 are all 
embryonic lethal (Bourdeau et al., 1999; Chang et al., 1999; Dickson et al., 1995; 
Oh et al., 2000; Oshima et al., 1996; Sinha et al., 2004; Urness et al., 2000).  At 
least 50% of the TGFβ1 and TGFβ type II receptor null mice die in utero from 
defects in the yolk sac vasculature by embryonic day 11.5.  Alk1, endoglin and 
SMAD5 knockouts succumb to intrauterine death around midgestation due to 
hemorrhaging from dilated and fragile vessels.  Further highlighting the 
importance of TGFβ intracellular signaling specifically in smooth muscle 
differentiation, knockout of either endogelin or Alk1 lead to a loss of smooth 
muscle cells that coat the dorsal aorta (Li et al., 1999; Oh et al., 2000; Sinha et 
al., 2004).  
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 TGFβ has the ability to up-regulate the expression of several smooth 
muscle markers, including SM22α, SM-α-actin and h1-calponin during 
myofibroblast differentiation (Bjorkerud, 1991; Sinha et al., 2004).  Inactivating 
TGFβ1, the TGFβ type II receptor, SMAD2 and SMAD3 in an embryonic stem 
cell – embroid body model of smooth muscle differentiation attenuated 
expression of many smooth muscle markers including SM MHC, SM- α-actin and 
SM22α (Sinha et al., 2004).  In addition, the SM-α-actin promoter was found to 
be regulated by both SMAD2 and SMAD3; whereas, SM-MHC only required 
SMAD2 for proper transcription (Sinha et al., 2004).  The authors note that this 
difference in requirement of SMADs could be due to the fact that SM-α-actin is 
also expressed in the myofibroblast and other cell types, indicating that perhaps 
SMAD2 is more important for regulation of smooth muscle cell differentiation 
(Sinha et al., 2004).  Overall, these findings therefore indicate that TGFβ1 
signaling, specifically through SMAD2 and SMAD3, has an important role in the 
development of smooth muscle cells. 
 Another factor implicated in smooth muscle cell differentiation is GATA6.  
GATA6 is a member of the GATA family zinc-finger transcription factors.  Studies 
have shown that GATA6 is the only member of this family to be expressed in 
vascular smooth muscle cells (Lepore et al., 2005).  Targeted knockout of 
GATA6 causes embryonic lethality at embryonic day 6.5 from a defect in visceral 
endoderm formation prior to vascular smooth muscle development (Lepore et al., 
2005; Morrisey et al., 1998).  Even though GATA6 is not expressed in all types of 
smooth muscle, studies have shown that GATA6 weakly activates the SM-MHC 
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promoter and that GATA6 in combination with cysteine-rich protein 2 (CRP2) 
activates serum response factor-dependent smooth muscle marker transcription 
(Chang et al., 2003; Wada et al., 2002; Wada et al., 2000).  These findings all 
indicate that GATA6 has a role in regulating the differentiation of smooth muscle 
cells; however, this type of regulation may be restricted to vascular smooth 
muscle. 
 
 iv.  SRF’s Role in Smooth Muscle Differentiation 
 
In 1984, Greenberg and colleagues found that cFos transcription in 
quiescent cells could be stimulated by serum (Chai and Tarnawski, 2002; 
Greenberg and Ziff, 1984).  Upon further investigation, it was determined that 
serum was able to activate the cFos promoter due to the presence of a specific 
DNA element upstream of the transcriptional start site in the promoter.  This 
element has the general consensus sequence CC(A/T)6GG and was named 
Serum Response Element (SRE) (Chai and Tarnawski, 2002).  Treisman later 
identified the transcription factor that bound to this specific sequence as a dimer 
and named it Serum Response Factor (SRF) (Chai and Tarnawski, 2002; 
Treisman, 1986).  The full-length mRNA transcript of SRF contains seven exons; 
however, due to alternative RNA splicing, it has been shown that four isoforms of 
SRF exist in the mouse:  (a) SRF-L, or full-length SRF, (b) SRF-M, which lacks 
exon 5, (c) SRF-S, which lacks exons 4 and 5, and (d) SRF-I, which contains 
only exons 1,2,6, and 7 (Chai and Tarnawski, 2002; Kemp and Metcalfe, 2000).  
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The resulting SRF proteins are 67, 62, or 48 kDa, depending on the isoform.  It is 
important to note that the SRF-L isoform corresponds to the dominant isoform 
found in the human, and the SRF-M isoform functions as a dominant negative of 
the full-length wild type (Belaguli et al., 1999; Chai and Tarnawski, 2002).  SRF 
contains three major conserved domains (Figure 1):  (a) MADS box, which 
serves as a DNA-binding motif, (b) several phosphorylation sites, which allow for 
post-translational regulation of SRF, and (c) transactivation domain, which is 
located at the C-terminus of SRF. 
Expression of SRF in the chicken and mouse provide strong evidence for 
a role of SRF in smooth muscle differentiation.  In the adult chicken, SRF 
expression is only detected in tissues of mesodermal and neuroectodermal origin 
(Arsenian et al., 1998; Croissant et al., 1996).  During gastrulation in the chicken, 
SRF mRNA is localized to the primitive streak, the neural groove, the lateral plate 
and the precardiac splanchnic mesoderm, the myocardium and the somites 
(Arsenian et al., 1998; Croissant et al., 1996).  In an adult mouse the highest 
levels of SRF mRNA can be seen in the skeletal, cardiac and smooth muscle 
tissues. During development SRF mRNA is highly expressed in the medial 
smooth muscle layer of the vessels, the myocardium of the heart and the 
myotomal portions of the somites (Arsenian et al., 1998; Belaguli et al., 1997).   
As a transcription factor, SRF is involved in multiple pathways that 
regulate disparate processes.  SRF is critical for the differentiation of skeletal, 
cardiac and smooth muscle lineages (Owens et al., 2004; Pipes et al., 2006).  
SRF regulates smooth muscle differentiation through its interaction with various 
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Figure 1.  Schematic of functional domains of serum response factor (SRF).  SRF 
contains a MADS domain, which serves as a DNA-binding motif; several 
phosphorylation sites, which allow for post-translational regulation of SRF; and a 
transactivation domain, which is located at the C-terminus of SRF. 
coactivators and/or cofactors such as myocardin, the myocardin family members 
MKL1 (MRTFA) and MRTFB (Behrens and Lustig, 2004; Wang et al., 2001), 
Mhox (Owens et al., 2004), Nkx3.1, Nkx3.2, Nkx2.5 (Carson et al., 2000; Nishida 
et al., 2002; Phiel et al., 2001), Barx2, Barx1b (Herring et al., 2001; Nakamura et 
al., 2001) and GATA6/CRP2 (Chang et al., 2003). 
The members of the myocardin family of SRF coactivators are very 
powerful activators of the smooth muscle differentiation program (Pipes et al., 
2006). The expression of myocardin itself is restricted to cardiac and smooth 
muscle-specific genes (Wang et al., 2001).  By forming a ternary complex with 
SRF and CArG elements, myocardin stimulates transcription of CArG-dependent 
muscle specific genes (Pipes et al., 2006).  The interaction of myocardin with 
SRF is crucial because myocardin itself does not bind directly to DNA, whereas 
SRF does.  The importance of myocardin in vascular smooth muscle 
development was demonstrated by analysis of myocardin knockout mice, which 
exhibited a lack of differentiated vascular smooth muscle cells and consequently 
died during embryonic development (Chen et al., 2003).   
In addition, myocardin related transcription factor A (MRTFA), which is 
expressed in a wider array of tissues, can also activate smooth muscle gene 
expression when over-expressed in fibroblasts, indicating that MRTFA may also 
regulate smooth muscle differentiation via interactions with SRF (Al-Aynati et al., 
2004; Pipes et al., 2006; Wang et al., 2002).  In support of this proposal siRNA 
mediated knockdown of MRTFA in rat vascular smooth muscle cells attenuated 
expression of CArG-dependent smooth muscle marker genes (Yoshida et al., 
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2007).  However, MRTFA knockout mice do not exhibit defects in smooth muscle 
cells although expression of smooth muscle-specific genes was attenuated in 
myoepithelial cells of the mammary gland (Li et al., 2006).  The discordance 
between these in vivo and in vitro data suggest that myocardin family members 
may have partially redundant functions such that one family member may be able 
to compensate for the loss of another family member in vivo.  
As with MRTFA, myocardin related transcription factor B (MRTFB) is also 
more widely expressed than myocardin (Du et al., 2003), and inactivation of both 
MRTFA and MRTFB is required to block Rho-A-dependent SRF target gene 
activation (Cen et al., 2003; Li et al., 2005).  However, unlike MRTFA, despite its 
potent transcriptional activation domain, MRTFB is only a weak coactivator (Li et 
al., 2005; Wang et al., 2002).  In support of the idea that MRTFB also plays a role 
in regulating smooth muscle differentiation, MRTFB knockout mice are 
embryonic lethal at embryonic day 13.5 to 14.5 (Li et al., 2005; Oh et al., 2005; 
Wei et al., 2007).  Mice deficient of MRTFB displayed defective brachial arch 
arteries and cardiac outflow tracts.  MRTFB null mice also demonstrated a lack of 
SM-α-actin in vascular smooth structures derived from neural crest cells (Li et al., 
2005; Oh et al., 2005), indicating that MRTFB plays a role in smooth muscle cell 
differentiation.  However, even though MRTFB is expressed in the embryonic 
heart and peripheral vasculature, these structures are normal in MRTFB 
knockout mice and only secondary vascular structures such as the brachial arch 
arteries and cardiac outflow tracts were affected (Li et al., 2005; Oh et al., 2005).  
Additional defects in MRTFB null mice include abnormal liver and portal vascular 
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development (Wei et al., 2007).  Nonetheless, since myocardin knockout mice 
are still embryonic lethal at embryonic day 10.5 when MRTFB is present, MRTFB 
cannot compensate for myocardin at this stage (Li et al., 2005; Oh et al., 2005). 
Another factor that affects how SRF regulates the differentiation of smooth 
muscle cells is Mhox.  Mhox has been shown to dramatically increase SRF 
binding to the CArG element in the SM-α-actin promoter (Hautmann et al., 1997; 
Owens et al., 2004).  This data has indicated that a homeodomain region in near 
proximity to one of the CArG elements in the SM-α-actin promoter is important 
for regulating SRF’s activity.  A further piece of evidence for this idea is that the 
over-expression of Mhox stimulated the SM-α-actin promoter in cultured smooth 
muscle cells (Owens et al., 2004).  In addition, studies have suggested a role for 
Mhox in angiotensin II-mediated smooth muscle differentiation.  Angiotensin II is 
capable of increasing expression of Mhox, which then subsequently enhances 
binding of SRF to either of the CArG elements in the SM-α-actin promoter 
(Owens et al., 2004). 
Nkx, Barx and GATA6 are additional factors that have been shown to 
regulate SRF and smooth muscle cell differentiation through forming a ternary 
complex with SRF.  Both Nkx and Barx are homeodomain-containing proteins 
that may function in a similar fashion to Mhox; whereas, GATA6 is a zinc finger 
protein.  A study by Nishida, et al., illustrated that a trimeric complex of GATA6, 
Nkx3.2 and SRF specifically activated smooth muscle markers such as SM22α 
and caldesmon, but not the proliferation factor cFos (Nishida et al., 2002; Owens 
et al., 2004).   
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Another piece of evidence for SRF’s involvement in smooth muscle 
differentiation can be obtained from the study of SRF-null mice.  Global SRF 
knockout was embryonic lethal by embryonic day 12.5 (Arsenian et al., 1998).  
By embryonic day 7.5, the SRF-/- embryos were reduced in size compared to 
their heterozygous littermates and displayed an absence of a primitive streak 
(Arsenian et al., 1998). In addition, the SRF-/- embryos form a misfolded 
endoderm and ectoderm and fail to form the mesodermal layer, indicating that 
SRF is critical for formation of the mesoderm, from which most smooth muscle is 
derived (Arsenian et al., 1998).  The absence of a mesodermal layer was 
confirmed by lack of Brachyury expression, a major mesoderm marker (Arsenian 
et al., 1998).  The study also demonstrated decreased expression of SRF-
dependent genes, such as cFos and Egr1, in the SRF-/- embryos (Arsenian et al., 
1998).  Since expression levels were reduced but not obliterated, this suggests 
that SRF is important for proliferation, but regulation of transcription of these 
genes is also controlled by additional transcription factors.  In addition to SRF-
dependent proliferation genes, the lack of SRF affects the expression of smooth 
muscle markers as well.  At embryonic day 7.5 to 8.5, SRF-/- embryos show 
drastic decreases in expression of both smooth muscle α- and γ-actin (Arsenian 
et al., 1998).   
In order to study the role of SRF in smooth muscle development without 
the issue of embryonic lethality, SRF knockout studies have also been conducted 
at the adult stage by employing a Cre-Lox conditional recombination model.  Two 
independent studies created smooth muscle-specific, conditional SRF knockout 
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models by crossing mice with a floxed SRF allele with transgenic mice with SM-
CreERT2, which was under the control of the smooth muscle-specific promoter 
SM22α and was tamoxifen-inducible (Angstenberger et al., 2007; Mericskay et 
al., 2007).  Within 2-4 days post-induction of SRF knockout, the mutant mice 
became lethargic, had a distended abdomen, and began to stop eating food and 
excreting feces (Angstenberger et al., 2007); and by days 13 and 20 post-
induction, the mutant mice had severe dilation of both the small and large 
intestines (Mericskay et al., 2007).  Both studies indicated that the mutant mice 
die before their wild-type counterparts, and one study noted that there was 100% 
lethality of mutant mice by 16 days post-induction.  Upon further investigation, 
the studies found that the SRF knockout mice had quickly developed chronic 
intestinal pseudo-obstruction (CIPO, also known as megacolon), which is 
characterized by chronic intestinal dilation and defective peristalsis due to a loss 
of contractile proteins (Angstenberger et al., 2007; Mericskay et al., 2007).  This 
decrease in intestinal contraction was the reason for the observed lack of feces 
excretion in the mice.  As for the reduced expression of contractile proteins, the 
studies illustrated that the loss of SRF greatly affected expression of SM-α-actin, 
SM-γ-actin and SM-MHC, which are all members of the core components of the 
contractile apparatus in smooth muscle cells (Mericskay et al., 2007).  The 
expression of SM22α, h1-calponin, SM-MLCK and telokin were also decreased, 
but the expression of proliferation gene cFos was unchanged between knockouts 
and controls (Mericskay et al., 2007).  Therefore, the loss of SRF severely 
affected the ability of the smooth muscle cells to remain in a differentiated state. 
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Similarly, loss of SRF has been shown to play a role in obstructive bladder 
disease due to its regulation of smooth muscle (Levin et al., 2000; Owens et al., 
2004).  SRF also appears to be crucial in the upper gastrointestinal tract where 
studies indicate that it is required for esophageal and gastric ulcer healing (Chai 
et al., 2004; Chai et al., 2007).   
Another clinical area that SRF plays a large role in is cardiovascular 
disease (CVD).  According to the American Heart Association, CVD is the 
number one killer in the United States to date.  A recent study demonstrates that 
inactivation of SRF in the adult heart results in dilated cardiomyopathy, or an 
enlarged heart, which then leads to death only eight to ten weeks post-SRF loss 
as a result of heart failure (Parlakian et al., 2005).  In a fashion similar to this role 
of SRF, studies have also linked aberrant SRF function to atherosclerosis and 
hypertension due to its ability to regulate proliferation, migration and 
differentiation of vascular smooth muscle cells (Owens et al., 2004).  To further 
support the idea of SRF’s importance in vascular development, Holtz, et al., note 
that loss of SRF severely impairs proper remodeling of the vessels in the 
vasculature when SRF was specifically ablated from endothelial cells using an 
endothelial cell-specific promoter Tie2-Cre system (Holtz and Misra, 2008).  
Specifically, mutant embryos, or Tie2Cre+/-SRFf/f, exhibited cerebrovascular 
hemorrhaging and blood pooling starting at embryonic day 11.5, which 
progressed during development and became lethal by embryonic day 14.5 (Holtz 
and Misra, 2008).  Further investigation revealed that the hearts of mutant 
embryos were smaller than those of wild type embryos, and the muscular region 
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of the interventricular septum in the mutants was reduced in size (Holtz and 
Misra, 2008).  The vessels in the mutant embryos were also enlarged, most likely 
due to edema resulting from vascular insufficiency (Holtz and Misra, 2008).  
Thus, SRF is not only important in the development and differentiation of 
vascular smooth muscle cells, but it also has an important function in the 
regulation of endothelial cells during vascular development and remodeling. 
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B.  SRF’s Regulation of Proliferation, Motility, Apoptosis and Other Processes 
 
 As previously mentioned, SRF is involved in several pathways that 
regulate disparate processes.  In addition to muscle differentiation, SRF has 
been implicated in the regulation of proliferation (Chai and Tarnawski, 2002; 
Johansen and Prywes, 1994), motility (Chai and Tarnawski, 2002; Hill et al., 
1995) and apoptosis (Schratt et al., 2004; Vickers et al., 2004). 
The major pathway involved in SRF’s regulation of proliferation is the 
MAPK pathway. In the MAPK pathway, growth factors or serum stimulate the 
phosphorylation of ternary complex factor (TCF), which interacts with SRF.  Upon 
this phosphorylation, transcription of immediate early genes (IEGs), such as cFos 
and Egr1, is up-regulated in order to regulate proliferation (Treisman, 1994).  A 
recent study also documented the involvement of factors such as cFos, SRF, 
Elk-1 and myocardin during intestinal obstruction in a murine model.  The authors 
of this study demonstrated that in response to obstruction, myocardin expression 
in smooth muscle cells of the small intestine initially decreased; whereas, cFos 
expression initially increased due to increased SRF/Elk-1 binding to the cFos 
promoter (Chen et al., 2008).  After a period of time, expression of both 
myocardin and cFos returned to control levels, and hypertrophy became 
apparent (Chen et al., 2008).  This data indicates that initially the smooth muscle 
cells in the small intestine are losing a differentiated phenotype and gaining the 
ability to proliferate, which is then followed by hypertrophy of the smooth muscle 
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layer of the small intestine once the cells begin to re-differentiate into smooth 
muscle cells.  
Signaling through the RhoA pathway activates SRF independently of 
MAPK/TCF signaling.  The key protein in this signaling cascade is the myocardin 
family member MRTFA (MKL1, megakaryoblastic leukemia-1).  MRTFA interacts 
with SRF in order to stimulate transcription factors such as SRF itself, vinculin, 
and junB (Cen et al., 2004).  Upregulation of these factors allows SRF to regulate 
processes such as differentiation, migration, and adhesion.  
Although not as well studied, SRF has also been found to play a role in 
regulating apoptosis. SRF has been shown to be required for differentiation-
dependent expression of the anti-apoptotic factor Bcl-2 (Schratt et al., 2004).  In 
this study, Schratt, et al., notes that embryonic stem cells that are devoid of SRF 
display increased apoptosis.  SRF affects apoptosis through regulating 
transcription of Bcl2 by activating its promoter through binding at the CArG region 
(Schratt et al., 2004).  Similarly, Vickers, et al., demonstrated that SRF is 
necessary for another anti-apoptotic factor’s transcription, Mcl-1, through its 
interaction with the transcription factor Elk-1, as well as its own binding to the 
promoter (Vickers et al., 2004). 
Due to its regulation of proliferation, motility and apoptosis, SRF could 
potentially have a role in cancer progression. Several studies have demonstrated 
that an aberrant MAPKerk pathway leads to various forms of cancer through the 
upregulation of transcription factors, which causes increased proliferation (Fang 
and Richardson, 2005; Lu et al., 2005; Ludes-Meyers et al., 2001; Wang and 
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Olson, 2004).  Unlimited replication, or proliferation, and the ability to evade 
apoptosis are two hallmarks of cancer and cancer progression. 
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C.  Smooth Muscle Cell Phenotypic Modulation 
 
 Since cardiovascular disease remains the number one killer of Americans, 
understanding the molecular mechanisms of such pathology is imperative to 
finding therapies and potential cures.  The main school of thought is that smooth 
muscle cells found in the intima following vascular injury arise from pre-existing 
medial smooth muscle cells that migrate and undergo phenotypic modulation 
(Owens et al., 2004; Ross and Glomset, 1976a; Ross and Glomset, 1976b).  
However, it has also been suggested that since both cultured adventitial 
fibroblasts and cultured endothelial cells can be induced to express smooth 
muscle markers such as SM-α-actin and SM-MHC (Frid et al., 2002; Owens et 
al., 2004), perhaps they contribute to the smooth muscle cell population in the 
intima during vascular injury.  There has also been recent compelling evidence 
that this intimal smooth muscle cell population is derived from bone marrow-
derived cells (Owens et al., 2004; Remy-Martin et al., 1999; Simper et al., 2002).  
However, no matter the origin of this population of smooth muscle cells during 
vascular injury, several studies have focused on factors involved in regulating 
this process on the molecular level.   
 
 i.  Kruppel-like Factors (KLFs) 
 
 One family of transcription factors widely studied in their role of the 
phenotypic modulation of smooth muscle cells is the kruppel-like factors (KLFs).  
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The KLFs are a group of zinc-finger DNA-binding transcription factors that have 
three main distinguishing features (Haldar et al., 2007):  (a) three C-terminal 
Cysteine2/Histidine2 containing zinc fingers (Bieker, 1996; Turner and Crossley, 
1999), (b) the highly conserved sequence TGEKP(Y/F)X between zinc fingers 
(Dang et al., 2002) and (c) the ability to bind the consensus CACCC or the GT 
box (Bieker, 1996; Dang et al., 2002).  In mammals, 17 KLFs numbered 1 
through 17 have been identified and have functions in the heart, skeletal muscle 
and smooth muscle.   
 With respect to smooth muscle, KLFs 4,5,13 and 15 have been 
demonstrated to have a role in the phenotypic changes of vascular smooth 
muscle cells during injury.  Under basal conditions in the adult, KLF4 expression 
is extremely low; however, after vascular injury, KLF4 expression is drastically 
increased and peaks within 1-2 hours post-injury but returns to basal levels after 
24 hours (Haldar et al., 2007).  Various studies have implicated KLF4 in 
promoting the de-differentiation of a smooth muscle cell during vascular injury.  
For example, Owens, et al., showed that knockdown of KLF4 partially regulates 
the repressive effects of PDGF-BB on smooth muscle cell gene expression 
(Haldar et al., 2007; Liu et al., 2005), which could be a result of the repressive 
effect of KLF4 on myocardin’s activity (Du et al., 2003; Haldar et al., 2007; 
Parmacek, 2007; Pipes et al., 2006; Wang et al., 2003).  Conditional knockout of 
KLF4 results in a delay in the down-regulation of smooth muscle markers 
following vascular injury demonstrating an important role of KLF4 in this 
phenotypic modulation (Yoshida et al., 2008).  Consistent with these data KLF4 
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has been shown to attenuate expression of TGFβ1-dependent increases in 
SM22α and SM-α-actin (Haldar et al., 2007).   
 KLF5 is highly expressed in fetal smooth muscle, but is nearly undetected 
in basal conditions of adult smooth muscle cells.  However, in a fashion similar to 
KLF4, KLF5 expression after vascular injury or angiotensin II treatment is 
dramatically increased, which may be regulated by the intracellular signaling of 
survivin and/or the MAPK pathways (Haldar et al., 2007; Hoshino et al., 2000; 
Nagai et al., 2005; Sakamoto et al., 2003).  Studies indicate that the highest 
expression of KLF5 post-injury is in the neointimal smooth muscle cells (Haldar 
et al., 2007).  Global knockout of KLF5 is embryonic lethal, but KLF5-/+ mice are 
viable (Haldar et al., 2007; Shindo et al., 2002).  Post-vascular injury, these mice 
have reduced neointimal formation, smooth muscle proliferation and perivascular 
fibrosis, suggesting that similar to KLF4, KLF5 has a role in vascular remodeling 
after injury.  Furthermore, over-expression of KLF5 increases expression of 
factors such as PDGF-A and B, PAI-1, iNOS and VEGF-R (Haldar et al., 2007; 
Nagai et al., 2005) that are increased following vascular injury.  Importantly, 
KLF5 has been shown to regulate smooth muscle through its interaction with 
chromatin remodeling factors.  For instance, interaction with p300 allows for 
increased activity of KLF5, which is partially mediated by the acetylation of KLF5 
itself (Haldar et al., 2007; Miyamoto et al., 2003).  In addition, HDAC1 can 
interact with KLF5 to inhibit KLF5 from binding to DNA, and myeloid leukemia 
associated oncoprotein SET can inhibit KLF5 activity by negatively regulating 
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KLF5’s ability to bind DNA, to transactivate target promoters and to exhibit pro-
proliferative effects (Haldar et al., 2007; Miyamoto et al., 2003). 
 Another Kruppel-like factor involved in smooth muscle regulation is 
KLF13.  While KLF13 is well described for its activity in cardiac muscle, KLF13 is 
much less studied than other KLFs with regard to smooth muscle.  However, one 
study has investigated it role in smooth muscle phenotypic modulation.  In this 
study, the authors report that KLF13, or basic transcription element-binding 
protein (BTEB 3), can activate the minimal promoter of SM22α, which is a 
smooth muscle-specific gene (Martin et al., 2003); yet, further investigation is 
required to elucidate the full function of KFL13 in smooth muscle. 
 A final KLF that has been shown to be involved in smooth muscle 
phenotypic modulation is KLF15.  In contrast to KLF4 and KLF5, KLF15 is highly 
expressed at basal levels in the adult; however, upon vascular injury or pro-
proliferative signals, KLF15 expression is dramatically reduced (Haldar et al., 
2007).  Over-expression of KLF15 leads to a potent inhibition of proliferation in 
cultured smooth muscle cells, and KLF15-/- mice display exaggerated neointimal 
response to vascular injury (Haldar et al., 2007).  Thus, KLF15 opposes the role 
of KLF5, and it is possible that a balance between these factors is crucial in the 
mechanistic response of smooth muscle cells to vascular injury. 
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 ii.  Platelet Derived Growth Factor (PDGF) 
 
 Promotion of proliferation and migration of smooth muscle cells 
accompanied by the downregulation of smooth muscle markers can be regulated 
by platelet derived growth factor (PDGF).  PDGF is a powerful chemoattractant 
that is produced by activated platelets and lesion macrophages (Ferns et al., 
1991; Heldin et al., 1998; Owens et al., 2004).  PDGF is expressed as a dimer of 
the isoforms PDGF-A and PDGF-B, which are connected by disulfide bonds 
(Heldin and Westermark, 1990; Owens et al., 2004).  Similarly, PDGF has two 
receptors:  PDGFR-α and PDGFR-β.  These receptors are tyrosine kinases and 
can be activated by PDGF-A alone, or either PDGF-A or PDGF-B, respectively 
(Owens et al., 1996).  Several studies have investigated the function of PDGF 
and its receptors as related to smooth muscle.  Global knockout of either PDGF 
isoform or either PDGF receptor is embryonic lethal (Bostrom et al., 1996; Levin 
et al., 2000; Owens et al., 2004; Soriano, 1994; Stenmark et al., 2000),  but 
ApoE-/- mice where both PDGFR-α and PDGFR-β have been inhibited exhibit 
decreased recruitment of smooth muscle cells in the neointimal region of an 
atherosclerotic lesion (Sano et al., 2001).  Additional studies using cultured 
embryonic liver cells deficient in PDGF-B introduced into lethally irradiated  
ApoE-/- mice found that the presence of smooth muscle cells in the fibrous cap in 
an atherosclerotic lesion of the ApoE-/- mice was delayed (Kozaki et al., 2002; 
Owens et al., 2004).  Similar results were seen in an analogous model where 
both PDGF receptors were inhibited with synthetic compounds (Kozaki et al., 
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2002; Owens et al., 2004).  Thus, it appears that inhibition of either PDGF and/or 
PDGF signaling attenuates but does not block smooth muscle cell migration and 
proliferation in a vascular lesion. 
 
 iii. Matrix metalloproteinases (MMPs) 
 
 Smooth muscle cells and macrophages produce endopeptidases called 
matrix metalloproteinases (MMPs).  These MMPs are thought to play a role 
during the degradation and remodeling of the extracellular matrix of an 
atherosclerotic plaque (Galis and Khatri, 2002; Owens et al., 2004).  Several 
factors have been linked to the regulation of MMP expression in vivo in response 
to vascular injury in order to aid in the phenotypic modulation of smooth muscle 
cells.  However, it is ultimately the balance between the expression of MMPs, the 
expression of their inhibitors (tissue inhibitor of metalloproteinase, or TIMPs) and 
the production of matrix by smooth muscle cells that determines the stability of a 
plaque (Owens et al., 2004).  For example, in the arteries of healthy individuals, a 
normal ratio of constitutively expressed MMP-2 (72-kDa gelatinase) and TIMP-
1/TIMP-2 exists, by which the matrix is maintained (Galis and Khatri, 2002; 
Owens et al., 2004).  However, as an atherosclerotic lesion begins and continues 
to develop, this normal ratio begins to favor the MMPs.  This change in ratio is 
most likely due to increased expression of MMP-3 (stromelysin) and MMP-9 (92-
kDa gelatinase) (Galis and Khatri, 2002; Owens et al., 2004).  Interestingly, a 
study by Galis, et al., demonstrated that the smooth muscle cells in the shoulder 
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region of an atherosclerotic plaque expressed high levels of both MMP-3 and 
MMP-9, which indicated to the authors that these MMPs may aid in the 
destabilization and rupture of a plaque as well as the recruitment and migration 
of smooth muscle cells to form a plaque (Galis et al., 1994; Owens et al., 2004).  
Supporting this proposal, MMP-9-deficient mice have reduced intimal smooth 
muscle cell hyperplasia and decreased late lumen loss following vascular injury 
(Galis et al., 2002).  Overall, the MMPs appear to have a critical role in the 
phenotypic modulation of smooth muscle cells during vascular injury; however, 
much remains to be elucidated about the detailed mechanism of environmental 
cues that regulate the MMPs. 
 
 iv.  Transforming Growth Factor Beta-1 (TGFβ1) 
 
 As previously described, TGFβ has the ability to induce expression of 
smooth muscle markers such as SM-α-actin and SM-MHC during differentiation.  
In addition to this role in differentiation, TGFβ can also regulate the phenotype of 
smooth muscle cells during vascular injury.  For instance, in the vascular balloon 
injury model, studies note that TGFβ expression is dramatically increased within 
6 to 24 hours post-injury (Majesky et al., 1991; Owens et al., 2004).  By over-
expressing TGFβ, the formation of neointima, the deposition of matrix and the 
proliferation of smooth muscle cells is drastically decreased (Smith et al., 1999), 
which further illustrates a role for TGFβ in regulating smooth muscle cells during 
vascular injury.  Furthermore, evidence supports the idea that TGFβ signaling 
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has a protective effect against atherosclerotic plaque formation in that the 
smooth muscle cells of advanced plaques tend to have mutations in the TGFβ 
receptor type II, which decreases the sensitivity of these cells to TGFβ (Massari 
and Murre, 2000; Owens et al., 2004).  Similarly, patients with unstable angina 
are inclined to have decreased levels of circulating plasma TGFβ (Grainger et al., 
1995; Owens et al., 2004).  Another study demonstrated that inactivating TGFβ1, 
TGFβ2 or TGFβ3 all lead to an accelerated development of atherosclerotic 
plaques by 15 weeks post-treatment, and this was accompanied by the increase 
in the presence of inflammatory cells along with a decrease in the amount of 
collagen (Mallat et al., 2001).  This data thereby indicates that TGFβ normally 
functions to decrease inflammation while contributing to matrix production of 
smooth muscle cells, which may lead to plaque stabilization. 
 
 v.  Apoptosis and Senescence in Modulation of Smooth Muscle Cell 
Phenotype during Vascular Remodeling   
 
 Another level of regulation of smooth muscle cell phenotypic modulation 
can be seen when examining the role of apoptosis, or programmed cell death, in 
vascular remodeling.  Indeed several studies have illustrated the importance of 
apoptosis during vascular wall remodeling in multiple cardiovascular diseases 
including hypertension, restenosis, aneurysms and atherosclerosis (Bennett et 
al., 1995; Bochaton-Piallat et al., 1995; Hamet et al., 1995; Korshunov and Berk, 
2008; Lopez-Candales et al., 1997).  For example, one study demonstrated that 
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compared to symptomatic atherosclerotic plaques, asymptomatic plaques have 
decreased expression of the antiapoptotoic factors cIAP2, xIAP and survivin, but 
the plaques have higher expression of SM-MHC, proliferating cell nuclear antigen 
(PCNA) and p50 subunit of nuclear factor-κB (NF-κB) (Korshunov and Berk, 
2008; Moran and Agrawal, 2007).   
 Recent studies have also determined that MMPs have a role in 
propagating vascular smooth muscle apoptosis during vascular remodeling.  The 
collagen fragments released by MMPs are thought to mediate the calpain-
dependent inactivation of the antiapoptotic factors xIAP (Korshunov and Berk, 
2008; von Wnuck Lipinski et al., 2006b).  However, another study shows that 
vascular smooth muscle cells appear to be protected from apoptosis by 
degraded collagen though αvβ3 integrin-mediated activation of NFκB and IAPs 
(Korshunov and Berk, 2008; von Wnuck Lipinski et al., 2006a).  Despite the 
discrepancy in results, both studies illustrate the importance of the extracellular 
matrix in regulating vascular smooth muscle cell apoptosis. 
 In addition to the vital role of the extracellular matrix in the phenotypic 
modulation of smooth muscle cells during vascular remodeling, other studies 
indicate that oxidative stress and inflammation have roles in this process.  For 
example, during neointima formation and transplant vasculopathy, a NFκB-
dependent gene, A20, was shown to have dual roles.  Not only did A20 have 
anti-inflammatory and antiapoptotic effects on medial vascular smooth muscle 
cells (increases in p21 and p27), but it also had sensitizing effects of neointimal 
vascular smooth muscle cells to apoptosis through a nitric-oxide-synthase-
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dependent pathway (Daniel et al., 2006; Korshunov and Berk, 2008; Patel et al., 
2006).   
 Not only has apoptosis been shown to have a critical role in vascular 
smooth muscle cell phenotypic modulation during vascular remodeling, but 
senescence has also been shown to have a role in this process, specifically in 
atherosclerosis.  The state of cellular senescence is defined as irreversible cell 
cycle arrest and the exhaustion of replicative potential (Gorenne et al., 2006; 
Hayflick, 1965).  Vascular smooth muscle cells undergoing senescence have an 
enlarged, flattened and stellate morphology with increased presence of 
cytoplasmic vacuoles and lysosomes (Goldstein, 1990; Gorenne et al., 2006).  In 
addition, these senescent cells have shorter telomeres and express high levels of 
markers of senescence, such as senescence-associated β-galactosidase 
(SAβG), and cell cycle regulators, such as p16 and p21 (Gorenne et al., 2006).  
Importantly, all of these characteristics of senescence have been demonstrated 
to be present in the medial vascular smooth muscle cells of atherosclerotic 
plaques (Bauriedel et al., 1999; Bennett et al., 1995; Gorenne et al., 2006; Mosse 
et al., 1985; Ross et al., 1984).   
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D.  Chromatin Remodeling Enzymes’ Roles in Development and Differentiation 
 
 i.  Introduction to Types of Chromatin Remodeling Enzymes 
 
Chromatin is defined as the entire complex of a cell’s DNA and associated 
proteins (Berg, 2002).  The building blocks of chromatin are the repeating 
nucleosomes, which consist of the histone octamer wrapped by approximately 
145 base pairs of DNA and approximately 55 base pairs of linker DNA between 
nucleosomes.  The histone octamer consists of four major histones: H2A, H2B, 
H3, and H4.  Each of these histones forms a dimer within the octamer.  Histone 
H1 is found in the linker DNA in front of the octamer (Berg, 2002). 
 In vivo chromatin exists in two states:  euchromatin and heterochromatin.  
Euchromatin is classified as transcriptionally active, or open chromatin.  This type 
of chromatin has irregularly spaced nucleosomes, and it is relatively accessible 
to nucleases and exhibits nuclease-hypersensitve sites that indicate the 
presence of sequence-specific DNA-binding proteins, or transcription factors 
(Gaszner and Felsenfeld, 2006).  Another descriptive characteristic of 
euchromatin is the presence of highly acetylated histones; hence enzymes that 
acetylate histones, the histone acetyl transferases (HATs), aid in the propagation 
of euchromatin.  Heterochromatin, on the other hand, is transcriptionally inactive, 
or closed, condensed chromatin.  Heterochromatin has significantly reduced 
sensitivity to nuclease digestion as compared to euchromatin (Gaszner and 
Felsenfeld, 2006).  In contrast to euchromatin, histones of heterochromatin are 
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mostly deacteylated, while instead they are hypermethylated at residues such as 
histone H3 at Lysine 9 and Lysine 27.  In addition to inactivating histone 
modifications, such as methylation, heterochromatin also displays extensive CpG 
DNA methylation, indicating inaccessible regions of DNA (Gaszner and 
Felsenfeld, 2006).  Whereas euchromatin is propagated by HATs, 
heterochromatin is spread through the activity of histone and DNA methyl 
transferases (HMTs and DMTs), as well as histone deacetylase complexes 
(HDACs).   
Since its conception, the idea of chromatin remodeling has evolved into 
multiple definitions.  In general chromatin remodeling can be defined as any 
event that alters the structure of a chromatin region to change histone-DNA 
interactions (Aalfs and Kingston, 2000; Lusser and Kadonaga, 2003).  To 
accomplish this alteration of chromatin structure, two main mechanisms exist. In 
the first, ATP-dependent remodeling complexes use ATP as an energy source to 
rearrange nucleosomes (Aalfs and Kingston, 2000).  Secondly, remodeling 
complexes covalently modify histone tails to change DNA-histone interactions 
and to alter the recruitment of other proteins to the nucleosomes (Aalfs and 
Kingston, 2000).   
Processes such as DNA transcription, replication, recombination, and 
repair rely on this rearrangement of chromatin structure.  For example, the 
promoter of a specific gene must be accessed by various transcription factors 
and the basal transcription machinery in order to initiate transcription.  Chromatin 
remodeling complexes thus alter the structure of the chromatin to allow access to 
 32
these factors required for gene transcription. Whether a specific transcription 
factor binds to DNA at its consensus sequence and then recruits the chromatin 
remodeling complex to remodel chromatin allowing access to the basal 
transcription machinery, or whether the chromatin remodeling complex changes 
the conformation and then allows for the transcription factor to bind DNA largely 
remains to be elucidated.  Initial observations suggest that this is likely to be 
different for each transcription factor analyzed and likely also gene specific.  In 
general chromatin remodeling involves multiple steps, which might include 
numerous transcription factors, and possibly even several, distinct chromatin 
remodelers (Aalfs and Kingston, 2000). 
 Covalent modification of histones and the subsequent recruitment of 
specific binding proteins has led to the histone code hypothesis.  This hypothesis 
states that specific post-translational covalent modifications of the histones’ tails, 
including phosphorylation, ubiquitination, sumoylation, acetylation and 
methylation, function to recruit unique proteins either alone or in combination with 
other modifications, such as DNA modifications that regulate gene transcription, 
replication and repair (Jenuwein and Allis, 2001).  For example, many regulatory 
proteins contain tandem bromodomains.  The bromodomain preferentially binds 
to diacetylated histone tails at lysine residues on histone H3 or H4 (Jenuwein and 
Allis, 2001).  Binding of such factors is thought to stabilize the chromatin 
structure and aid in activation of transcription.  Whereas the bromodomain is 
recruited to acetylated histone tails, the chromodomain recognizes methylated 
histone tails.  However, whether this recruitment supports transcriptional 
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activation or inactivation depends on the number of chromodomains within the 
regulatory protein.  For instance, heterochromatin protein 1 (HP1) contains a 
single chromodomain and is recruited to the inactivating methylations such as 
methylated H3 at lysine 9 or 27 (Jenuwein and Allis, 2001).  On the other hand, 
two tandem chromodomains are recruited to methylations on H3 at lysine 4, 
which are characteristic of sites of transcriptional activation (Jenuwein and Allis, 
2001).  In response to DNA double strand breaks, H2A.X – a variant of histone 
H2 – is phosphorylated and this serves as a signal to recruit regulatory proteins 
involved in DNA repair (Escargueil et al., 2008). 
 
 ii.  ATP-dependent Chromatin Remodeling Enzymes 
 
As mentioned in the previous section, a multitude of chromatin remodeling 
enzymes exist, but structurally three main categories exist:  (a) DNA-modifying 
enzymes that methylate CpG-rich sequences, (b) histone-modifying enzymes 
that covalently modify histones by methylation, acetylation, phosphorylation, or 
ubiquitination, and (c) ATP-dependent chromatin remodeling complexes that 
reorganize nucleosomes (Sif, 2004).   
 The ATP-dependent chromatin remodeling enzymes all belong to the 
SNF2 family of DNA-dependent ATPases, meaning that they all have a helicase-
like ATPase domain (de la Serna et al., 2006).  Many of these enzymes are 
highly conserved across species and have numerous subfamilies.  These 
subfamilies, or subclasses, are determined by the functional domains of each 
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enzyme.  There are three major subclasses:  the SWI/SNF family, the SWI 
(ISWI) family and the CHD family (de la Serna et al., 2006).  The SWI/SNF family 
is characterized by the ability to bind to acetylated histones via their 
bromodomain.  This group includes proteins such as brahma (BRM), brahma-like 
gene 1 (Brg1) and Snf2.  The SWI (ISWI) family of proteins, on the other hand, 
contain not a bromodomain, but a SANT domain.  The SANT domain is thought 
to bind to modified histones, and this family includes Isw1, Isw2, SNF2H and 
SNF2L.  The third subclass, or CHD class, is the chromodomain and helicase-
like domain family.  As the name implies, this subclass is characterized by its two 
amino-terminal chromodomains that recognize methylated histones.  This group 
contains the CHD proteins one through nine. 
As an example of ATP-dependent chromatin remodeling, Brg1 and Brm1, 
the ATPase subunits of the SWI/SNF ATP-dependent chromatin remodeling 
complexes, will be briefly discussed.  Recently our laboratory has demonstrated 
that Brg1 is required for MRTFA, a myocardin related transcription factor, to 
induce expression of smooth muscle specific genes in nonmuscle cells, but it 
does not affect expression of SRF-MRTFA-dependent immediate early genes 
(Zhang et al., 2007).  MRTFA is unable to induce expression of smooth muscle 
specific genes in SW13 cells that lack Brg1 or in 3T3 cells expressing dominant 
negative Brg1.  Reintroduction of Brg1 or Brm1 into SW13 restores their 
responsiveness to MRTFA (Zhang et al., 2007).  In addition, Brg1 is necessary 
for MRTFA to increase binding of SRF to the promoters of smooth muscle genes 
in primary smooth muscle cells.  These findings support the idea that ATP-
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dependent chromatin remodeling enzymes, specifically Brg1 in this case, might 
stabilize active chromatin and allow for transcription factor binding to the 
promoters of smooth muscle-specific genes in order to activate transcription in 
smooth muscle cells. 
 
 iii.  CHD Family and CHD8 
 
Since the CHD family currently has nine members that are defined by their 
chromodomains, it is important to define a chromodomain.  The chromodomain 
can be classified as a conserved region of approximately fifty amino acids that 
functions to bind DNA, RNA or methylated histones (Akhtar et al., 2000; 
Bouazoune et al., 2002; Cowell and Austin, 1997; Hall and Georgel, 2007; 
Marfella and Imbalzano, 2007).  Additionally, common to all CHD family 
members is the ATPase/helicase domain, which is very similar to the SWI2/SNF2 
ATPase.  Even though the chromodomain is the major domain that identifies 
these nine proteins, they can be further divided into subcategories based on their 
additional domains that are characteristic of their subfamily’s function.   
The first subfamily of CHD proteins includes CHD1 and CHD2.  This 
subfamily is defined by the presence of a DNA-binding domain within the C-
terminus, which preferentially binds to AT-rich regions of DNA (Delmas et al., 
1993; Hall and Georgel, 2007; Marfella and Imbalzano, 2007; Stokes and Perry, 
1995; Woodage et al., 1997).  CHD1 has been the most described CHD protein 
to date.  Studies have illustrated that CHD1 interacts with a number of 
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transcription factors.  For instance, Kelley, et al., demonstrated that CHD1 
colocalizes with the HMG box-containing protein and chromatin transcription 
coactivator, SSRP1 (Hall and Georgel, 2007; Kelley et al., 1999).  This data 
provides evidence of CHD members’ ability to associate with chromatin.  In 
addition, Tai, et al., demonstrated via yeast 2-hybrid assays that CHD1 interacts 
with the transcriptional corepressor NCoRand, as well as with HDAC1.  The 
interaction with HDAC1 indicated that CHD1 could be recruited by specific 
histone modifications (Hall and Georgel, 2007; Tai et al., 2003). CHD1 has been 
shown to interact with the histone acetyltransferase complexes SAGA and SILK 
to regulate transcription (Hall and Georgel, 2007; Pray-Grant et al., 2005).  In 
addition, Pray-Grant, et al., determined that one of CHD1’s two chromodomains 
was required for interaction specifically with histone H3 that is methylated at 
lysine 4 (Pray-Grant et al., 2005).  Another function of CHD1 is to aid in 
transcriptional initiation and elongation by interacting with Paf1, a cofactor of 
polymerase II, or Rtf1, a regulator of transcriptional elongation, at regions of 
actively transcribed genes (Hall and Georgel, 2007; Simic et al., 2003). 
The next subset of the CHD family includes CHD3 (a.k.a. Mi-2α) and 
CHD4 (a.k.a. Mi-2β).  These two members of the CHD family differ from the 
proteins in the first subset in that they lack the C-terminal DNA binding domain 
but have paired PHD (plant homeo domain) zinc-finger-like domains in the N-
terminus (Marfella and Imbalzano, 2007; Woodage et al., 1997).  These two CHD 
family members have been implicated as being the central components of the 
nucleosome-remodeling and histone deacetylase NuRD complex (Hall and 
 37
Georgel, 2007).  As a member of the complex, CHD3 interacts with the histone 
deactylases HDAC1 and HDAC2, and CHD4 binds these two proteins as well as 
Brg1, a component of the SWI/SNF remodeling complex (Bowen et al., 2004; 
Hall and Georgel, 2007; Shimono et al., 2003). 
Much less is known about the members of the third and final subset of 
CHD proteins.  This subfamily includes CHD5-CHD9, which is defined by the 
presence of BRK domains (Marfella and Imbalzano, 2007).  CHD6 has been 
demonstrated to interact with polymerase II, and it is present at sites of mRNA 
synthesis, suggesting a role in RNA activation and/or transcription (Hall and 
Georgel, 2007; Lutz et al., 2006).  Mutations in CHD7 appear to be critical for the 
development of CHARGE syndrome (coloboma of the eye, heart defects, atresia 
of the choanae, retardation of growth and/or development, genital and/or urinary 
abnormalities and ear abnormalities and deafness) (Hall and Georgel, 2007).  
CHD7 has also been implicated in the development of the human foregut 
(Brunner and van Bokhoven, 2005; Hall and Georgel, 2007).  CHD9 (a.k.a. 
CReMM) has been shown to play a role in osteoblast development (Benayahu et 
al., 2007; Shur et al., 2006).  As CHD8 is the main focus of this thesis 
dissertation, its known functions are now described in more detail. 
Sakamoto, et al., originally discovered duplin, which is an N-terminal 
splice variant of CHD8, as a component of the wnt signaling pathway.  Initially, 
duplin was cloned through its ability to bind dishevelled (Dvl) in a yeast two-
hybrid screen; however, after further investigation they determined that duplin 
bound directly to the Armadillo repeats of β-catenin, rather than to Dvl (Sakamoto 
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et al., 2000).  Duplin’s interaction with β-catenin within the nucleus of intact cells 
was found to inhibit wnt signaling by preventing β-catenin from binding to TCF4 
(Sakamoto et al., 2000).  Duplin was also found to be able to inhibit β-catenin’s 
ability to induce axis duplication in Xenopus (Sakamoto et al., 2000).  Recently, 
Thompson, et al., also demonstrated direct binding of CHD8 to β-catenin and that 
this interaction required the Armadillo repeats of β-catenin (Thompson et al., 
2008). They also showed that CHD8 localized to the promoter of β-catenin target 
genes Axin2, Dkk1 and Nkd3 and functioned to inhibit transcription of these 
genes under normal conditions, as loss of CHD8 caused modest, but significant 
increases in their transcription (Thompson et al., 2008). 
Further studies from the Kikuchi group determined that the nuclear 
localization of duplin itself was essential for its inhibitory effects on β-catenin 
signaling.  Kobayashi, et al., found that importin α bound to duplin at the basic 
amino acid clusters located from amino acids 500-584 of duplin (Kobayashi et al., 
2002).  Importantly, when this region of duplin was deleted, the authors noted 
that duplin was no longer expressed in the nucleus, rather it remained in the 
cytoplasm.  In addition, deletion of duplin’s amino acids 500-584 allowed for 
binding to β-catenin; however, this construct could no longer prevent wnt-
dependent activation of TCF-dependent transcriptional targets (Kobayashi et al., 
2002).  Hence, this data illustrates that duplin must be located in the nucleus to 
inhibit β-catenin signaling and that duplin’s interaction with importin α is most 
likely critical for this location. 
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Yamashina, et al., conducted a yeast two-hybrid screen of a mouse cDNA 
library, using the C-terminal half of duplin as bait (duplin amino acids 482-749).  
As a result, the authors identified PIAS3, a SUMO E3 ligase and negative 
regulator of STAT3 (Yamashina et al., 2006).  This interaction was confirmed to 
occur within intact cells and was localized to the nucleus (Yamashina et al., 
2006).  Since PIAS3 has the ability to sumoylate proteins, they investigated 
whether duplin could be sumoylated and found that Lys609 of duplin was indeed 
sumoylated; however, this modification had no effect on duplin’s function in the 
wnt signaling pathway (Yamashina et al., 2006).  In contrast, duplin inhibited LIF-
dependent STAT3 activity without preventing the phosphorylation and nuclear 
transportation of STAT3 (Yamashina et al., 2006).  Using electromobility shift 
assays (EMSA), it was shown that duplin inhibited STAT3 transcriptional activity 
by preventing STAT3 from binding to DNA, and duplin itself was also shown to 
directly interact with STAT3.  Yet, although both duplin and STAT3 can be 
sumoylated, duplin regulates STAT3 independent of this modification 
(Yamashina et al., 2006). 
Since duplin was shown to play a role in the wnt signaling pathway which 
is critical in development, a duplin knockout model was developed to determine 
whether duplin was also important in development.  It is important to note that 
although the previous studies with duplin may not necessarily translate into the 
same results for full-length CHD8 due to differences in functional domains, this 
knockout model would result in the loss of both duplin and CHD8 (Nishiyama et 
al., 2004).  Homozygous duplin knockouts were viable until embryonic day 8.5 
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and were completely resorbed by embryonic day 9.5 (Nishiyama et al., 2004).  
The duplin-/- embryos failed during gastrulation and lacked a primitive streak and 
mesodermal layer (Nishiyama et al., 2004).  In addition, these duplin-/- embryos 
exhibited massive amounts of apoptosis as visualized by TUNEL staining 
(Nishiyama et al., 2004). 
CHD8 has also been shown to function independent of wnt signaling to 
regulate boundary elements and to have an insulator function through an 
interaction with CTCF (Ishihara et al., 2006).  This study found that CHD8 bound 
directly to the zinc finger region of the chromatin insulator CTCF through the Brk 
domains of CHD8.  Through this interaction, CHD8 was able to locate to known 
CTCF binding sites, such as the differentially methylated region (DMR) of H19 
and the promoters of BRCA1 and c-myc, as visualized by chromatin 
immunoprecipitation assays (Ishihara et al., 2006).  CHD8 through its interaction 
with CTCF was found to be required for the imprinted expression of IGF2 and to 
be essential for the insulation of the H19 DMR region (Ishihara et al., 2006).  
CHD8 was also shown to participate in the prevention of spreading of CpG 
methylation or condensed chromatin in the BRCA1 and c-myc promoters, 
respectively (Ishihara et al., 2006).  Thus, these studies revealed a direct role of 
CHD8 in chromatin remodeling.  Furthermore, Thompson, et al., demonstrated 
that CHD8 has ATPase activity and mediates ATP-dependent remodeling of 
nucleosomes (Thompson et al., 2008). 
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E.  Rationale 
 
It is widely accepted that one mechanism by which SRF can distinguish 
between different pathways is through pathway-specific cofactor interactions. In 
order to determine whether SRF was regulated by additional cofactors, our 
laboratory conducted a yeast two-hybrid screen, using SRF as bait.  From this 
screen we identified the N-terminus of chromodomain helicase DNA binding 
protein 8 (CHD8).  As described above, CHD8 is an ATP-dependent chromatin 
remodeling enzyme. Our laboratory has previously demonstrated that another 
ATP-dependent chromatin remodeling enzyme, Brg1, regulates SRF’s activity in 
smooth muscle cells. It is also well known that SRF is crucial for smooth muscle 
development and plays an important role under physiological and pathological 
conditions. This dissertation, thus, focuses on this newly identified SRF cofactor, 
CHD8, and determines its role in transcription regulation in smooth muscle cells. 
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F.  Hypothesis 
 
 CHD8 regulates the chromatin structures of SRF-dependent genes to 
affect the phenotype of vascular smooth muscle cells. 
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CHAPTER II 
Methods 
 
A.  RNase Protection Assay   
 
 The RPA III™ protocol from Ambion was used to perform ribonuclease 
protection assays.  Briefly, a probe was designed to span the alternatively spliced 
exons that give rise to duplin and CHD8 such that the duplin mRNA will protect a 
318 nt fragment of the probe; whereas, CHD mRNA will protect a 150 nt 
fragment.  Mouse brain mRNA was used as a template for RT-PCR and the 
resultant fragment was cloned, sequenced and used as the probe for RNase 
protection analysis.  Twenty-five µg of RNA from each mouse tissue were subject 
to RNase protection analysis. 
 
B.  GST-pull Down Assays   
 
 A series of SRF deletion constructs fused to GST, which were described 
previously (Herring et al., 2001), were utilized.  In addition, a series of CHD8 
truncations were constructed in the pET vector to perform the reverse 
experiment; CHD8 truncations employed in experiments are indicated in the 
figure legends.  As it was previously shown that the N-terminal fragment of CHD8 
is sufficient to bind to SRF, further deletions of this region were be generated by 
PCR and cloned into pET28, which has a T7 epitope tag.  Bacterial proteins were 
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isolated, and GST-pull down assays were conducted as previously described 
(Herring et al., 2001).  Binding interactions were visualized using standard 
western blot techniques with primary antibodies against GST, T7 for pET vector 
fusion proteins. 
 
C.  Co-immunoprecipitation Assays  
 
 All coIP assays from mammalian cells were performed using the Active 
Motif® Nuclear coIP Kit, according to the protocol suggested by the manufacturer 
with a few minor adjustments.  Lysates were precleared for one hour with 50 µL 
of EZ view Protein A Sepharose (Sigma) beads (PAS) in 900 µL of IP wash 
buffer. PAS beads were washed twice for 5 minutes in IP wash buffer with 1 
mg/ml BSA and once for 5 minutes in wash buffer without BSA prior to addition to 
the antibody-lysate mixture.  Both SRF and CHD8 were immunoprecipitated from 
500 µg of nuclear extract with approximately 5 µg of protein-specific antibody or 
IgG control.  All conditions during the co-immunoprecipitation were low 
stringency.  Antibodies used for immunoprecipitation included SRF (Santa Cruz) 
and CHD8 (Proteintech). Standard western blot techniques were used to 
visualize the presence of CHD8 (Bethyl antibody) or SRF.  A10 vascular smooth 
muscle cells were utilized for collection of nuclear lysate.  All experiments were 
repeated at least three times using independent nuclear lysates. 
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D.  Cell Culture   
 
 All primary mouse cells and 10T1/2 mouse fibroblasts were cultured in 
DMEM supplemented with 10% FBS, 2 mM L-Glutamine, and 50 Units/ 50 µg 
penicillin/streptomycin.  A10 vascular smooth muscle cells (VSMCs) were 
cultured in DMEM supplemented with 20% FBS, 2 mM L-Glutamine, and 50 
Units/ 50 µg penicillin/streptomycin.  A10 cells were passaged every other day 
and plated at 1:3 dilutions until passage 23. 
 
E.  Adenovirus Construction and Cell Transduction   
 
 A previously published shRNA sequence directed to CHD8 was cloned 
into the AdenoX vector (BD Bioscience) (Ishihara et al., 2006).  The virus was 
packaged and harvested in HEK cells, according to the manufacturer’s protocol.  
Primary mouse colon, bladder or aortic SMC were be plated at a density of 5x104 
cells per well in 12-well plates and transduced with either CHD8 shRNA or 
control shRNA virus as previously described (El-Mounayri et al., 2005; Yin et al., 
2006; Zhou and Herring, 2005).  A minimum of triplicate wells of cells were 
infected with each virus, and all experiments were be repeated at least three 
times using independent preparations of smooth muscle cells. 
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F.  Serum Starvation/Stimulation During Adenoviral Infection  
 
 Mouse passage 1 colon SMCs were transduced as described above.  
After 24 hours of transduction, media was replaced with DMEM supplemented 
with 0.5% FBS.  After 24 hours in low serum media, the media on half of the 
samples was replaced with DMEM supplemented with 10% FBS.  Cells were 
incubated for 30 minutes or 2 hours to stimulate SRF-dependent growth factor 
responsive genes.  RNA was isolated after this time point for analysis of effects 
on SRF-dependent gene expression by quantitative RT-PCR. 
 
G.  TGFβ-induced Myofibroblast Differentiation  
 
 10T1/2 cells were plated in the afternoon at a density of 3x105 cells per 
well in a standard 6-well format.  After an overnight incubation at 37˚C with 5% 
CO2, cells were transduced as previously described in the methods with 
adenoviral vectors for shRNA targeting CHD8 as well as an shRNA control.  
However, instead of adding fresh full-serum media after the initial 4-hour 
incubation, media supplemented with 0.5% FBS was added after the virus was 
aspirated.  Following a 24-hour period at 37˚C with 5% CO2, cells were either 
given fresh 0.5% FBS media, or treated with TGFβ1 at a final concentration of 2 
ng/mL under low serum conditions.  Cells were treated for 24 hours and then 
collected for analysis of gene expression by quantitative RT-PCR.  
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H.  Quantitative RT-PCR (qRT-PCR)  
 
 For the RT-step, 0.5-1 µg of RNA was reverse-transcribed to cDNA using 
random hexamer primers (Invitrogen Superscript First-Stand Kit).  A 1:10 dilution 
of the resulting cDNA was used in a quantitative PCR reaction, following the 
methods for a 25 µL, 2-step cycling reaction from the ABgene qPCR with SYBR 
green kit.  Sequence-specific primers for SRF and its targets included the 
following: CHD8 sense CCAGCTCCAGCTCCAGCAC; anti-sense 
CCTGCAGTAGCAGCAACTCAG; SRF sense GTTCATCGACAACAAGCTGC; 
anti-sense CTGTCAGCGTGGACAGCTCATAG; cyclin D1 sense 
GCCAGAGGCGGATGAGAACAAGC; anti-sense GGTCACACTTGATGAC 
TCTGG; EGR1 sense GAGCACCTGACCACAGAGTC; anti-sense 
CCACAAAGTGTTGCCACTGTTG; α-actin sense CCAGAGTGGAGAAA 
GCCCAGC; anti-sense GGCTGTGCTGTCTTCCTCTTCAC; SM22α sense 
CGAAGCCAGTGAAGGTGCCTGAGAAC; anti-sense CCCAAAGCCATTAG 
AGTCCTCTGCACTGC; telokin sense GACACCGCCTGAGTCCAACCTCCG; 
anti-sense GGCTTTTCCTCAGCAACAGCCTCC; cMYC sense CCACC 
AGCAGCGACTCTGAA; anti-sense CTGTGCGGAGGTTTGCTGTG; 36B4 sense 
GGACCCGAGAAGACCTCCTT; anti-sense TGCTGCCGTTGTCAAACACC; and 
Birc5/survivin sense CTGGCCCTTCCTGGAGGA; anti-sense CTCGGTAGG 
GCAGTGGATGA. Primers for cFos and vinculin were obtained from Qiagen 
(QT00147308 and QT00158319, respectively). Each of these primer sets spans 
introns in their respective genes. 
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I.  Induction of Apoptosis   
 
 A10 vascular SMCs were plated at 5x104 cells per well in 12-well plates 
transduced in quadruplicate with either CHD8 shRNA, SRF shRNA, or control 
shRNA virus as previously described (El-Mounayri et al., 2005; Yin et al., 2006; 
Zhou and Herring, 2005).  After 72 hours of incubation at 37˚C with 5% CO2, 
cells were treated with 0.2 mM H2O2 for 6 hours.  Media was collected, and wells 
were washed twice with PBS, which was added to the collected media.  The 
pooled media and washes were spun at 2,000 rpm for two minutes at room 
temperature to accumulate any non-adherent cells.  The PBS and media were 
then aspirated and the pellet was washed once with PBS.  In the meantime, 100 
µL of RIPA lysis buffer was added to each well, and the cells were incubated on 
ice for 10 minutes.  Cells were then scraped into the corresponding tube with the 
cell pellet and incubated on ice an additional 5 minutes.  Tubes were then spun 
at 14,000 rpm for 2 minutes at 4˚C, and resulting supernatants were transferred 
to a fresh tube.  BCA assays were performed to ensure equal loading during 
protein separation by SDS-PAGE.  Standard western blot techniques were 
employed to visualize changes in protein expression. 
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J.  Western Blotting   
 
 For apoptosis studies, 20 µg of protein were loaded for each sample 
during SDS-PAGE.  Antibodies used include anti-SRF (Santa Cruz), anti-CHD8 
(Bethyl), anti-phospho-H2A.X (Upstate), anti-caspase-3 (Cell Signaling), anti-
cleaved-caspase-3 (Cell Signaling), anti-PARP (Santa Cruz), anti-GAPDH 
(Novus), anti-Bcl-2 (BD Biosciences), anti-Bcl-XL (Cell Signaling), anti-Mcl-1 
(Abcam), and anti-non-muscle-MHCIIb (Covance). For GST Pull Down assays, 
antibodies used included anti-T7 (Novagen).  GST was visualized via ponceau 
staining.  Secondary antibodies were used accordingly and included goat-anti-
rabbit-HRP and goat-anti-mouse-HRP. 
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CHAPTER III 
CHD8 binds SRF, promotes the expression of smooth muscle-specific genes and 
protects smooth muscle cells from apoptosis 
 
A.  Summary 
 Serum response factor (SRF) is a widely expressed protein that plays a 
key role in the regulation of smooth muscle differentiation, proliferation and 
migration.  It is generally accepted that one mechanism by which SRF can 
distinguish between stimulating differentiation, proliferation or migration is 
through pathway-specific cofactor interactions.  A novel SRF cofactor, 
chromodomain helicase DNA binding protein 8 (CHD8), was isolated from a 
yeast two-hybrid screen using SRF as bait. CHD8 is highly expressed in adult 
smooth muscle tissues.  Co-immunoprecipitation assays from cells demonstrated 
binding of the full-length SRF and endogenous CHD8 within cells.  Data from 
GST-pull down assays indicate that the N-terminus of CHD8 can interact directly 
with the MADS domain of SRF.  Adenoviral-mediated knockdown of CHD8 in 
smooth muscle cells resulted in statistically significant 10-20% attenuation of 
expression of SRF-dependent, smooth muscle-specific genes.  Knockdown of 
CHD8 did not affect the SRF-dependent induction of immediate early genes by 
serum.  In contrast, knockdown of either SRF or CHD8 in A10 vascular smooth 
muscle cells resulted in a marked induction of apoptosis, characterized by 
increased phospho-H2A.X, cleaved PARP and activated caspase-3.  These data 
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suggest that CHD8 may play a specific role in modulating SRF activity toward 
anti-apoptotic genes, thereby promoting smooth muscle cell survival. 
 52
B.  Introduction 
 SRF is a broadly expressed transcription factor that regulates disparate 
processes under both physiological and pathological conditions (Miano, 2003).  It 
has been implicated in a number of signaling pathways including the ras-raf- 
ERK-MAPK-cascade (Chai and Tarnawski, 2002; Johansen and Prywes, 1994), 
the RhoA small GTPase cascade (Chai and Tarnawski, 2002; Hill et al., 1995) 
and the muscle differentiation pathway (Miano et al., 2007; Owens et al., 2004; 
Pipes et al., 2006).  In the MAPK pathway, growth factors or serum stimulate the 
phosphorylation of the ternary complex factor (TCF) family of proteins, such as 
Elk1, which interact with SRF.  Upon this phosphorylation, transcription of 
immediate early genes (IEGs), such as cFos and Egr1, is up-regulatedd in order 
to promote proliferation (Treisman, 1994).  RhoA signaling stimulates production 
of filamentous actin and activates the dissociation of cytoplasmic MKL1 from 
globular actin, leading to nuclear accumulation and activation of MKL1 (Miralles 
et al., 2003).  Mkl1 then interacts with SRF in order to stimulate transcription of 
genes such as SRF itself, vinculin, and junB (Selvaraj and Prywes, 2004).  
Upregulation of these factors allows SRF to regulate processes such as 
differentiation, migration, and adhesion.  SRF is also critical for the differentiation 
of skeletal, cardiac and smooth muscle lineages (Miano et al., 2007; Owens et 
al., 2004; Pipes et al., 2006).  SRF regulates smooth muscle differentiation 
through its interaction with coactivators such as myocardin and the myocardin 
family members MKL1 (MRTFA) and MRTFB (Cen et al., 2004; Wang et al., 
2001).  In addition to its association with cofactors, the activity of SRF is also 
 53
regulated through modulation of nuclear translocation (Camoretti-Mercado et al., 
2000; Chai and Tarnawski, 2002), phosphorylation-dependent changes in DNA 
binding (Chai and Tarnawski, 2002; Manak and Prywes, 1991) and alternative 
RNA splicing (Belaguli et al., 1999; Chai and Tarnawski, 2002; Kemp and 
Metcalfe, 2000).  Global SRF knockout mice are embryonic lethal due to a failure 
in gastrulation. The SRF-/- embryos form a misfolded endoderm and ectoderm 
and fail to form the mesodermal layer, indicating that SRF is critical for formation 
of the mesoderm from which most muscle is derived (Arsenian et al., 1998).  To 
circumvent this embryonic lethality a number of groups have specifically ablated 
SRF in different muscle tissues.  These studies have shown that SRF is critical 
for the development of each muscle lineage (Angstenberger et al., 2007; Charvet 
et al., 2006; Mericskay et al., 2007; Niu et al., 2005).  Using a conditional smooth 
muscle-specific knockout system SRF deletion in adult mice quickly resulted in 
the development of chronic intestinal pseudo-obstruction (CIPO) (Angstenberger 
et al., 2007; Mericskay et al., 2007).  The CIPO was characterized by chronic 
intestinal dilation and defective peristatlsis due to a loss of contractile proteins, 
indicating that the expression of many contractile proteins is dependent upon 
SRF in adult mice. 
 In an attempt to identify other cofactors that regulate SRF activity we 
conducted a yeast two-hybrid screen, using SRF as bait (Herring et al., 2001).  
From this screen we identified the homeodomain protein Barx2 (Herring et al., 
2001) and a cDNA encoding the N-terminus of chromodomain helicase DNA-
binding protein 8 (CHD8).  CHD8 is a member of the CHD family of ATP-
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dependent chromatin remodeling proteins.  CHD proteins, such as CHD8, 
contain two tandem chromodomains, an ATPase domain and a helicase domain.  
In addition to these domains, CHD8 contains two homeodomain-like domains.  
Duplin, an N-terminal splice variant of CHD8 orginally discovered as a β-catenin-
binding protein (Sakamoto et al., 2000), contains only the first of the two 
chromodomains.  Chromodomains are regions of 40-50 amino acids that are 
involved in chromatin remodeling and gene regulation (Cavalli and Paro, 1998).  
These domains can serve as protein interaction modules, RNA-binding modules, 
or DNA-binding modules (Akhtar et al., 2000; Bouazoune et al., 2002; Cowell and 
Austin, 1997).  The chromodomains in CHD8 have been shown to specifically 
interact with histone H3 trimethylated at lysine 4 (Yuan et al., 2007).  CHD8 has 
been shown to exhibit ATP-dependent chromatin remodeling activity and to 
repress β-catenin target genes (Thompson et al., 2008).  CHD8 has also been 
shown to bind to the insulator binding protein CTCF (Ishihara et al., 2006), and  
the CHD8/CTCF complex has been shown to play an important role in the 
epigentic regulation of insulator sites.  Duplin/CHD8 knockout mice (both duplin 
and CHD8 were knocked-out) are embryonic lethal and failed to form a primative 
streak or the mesodermal layer during gastrulation, indicating that CHD8/duplin 
play a critical role in early development (Nishiyama et al., 2004).  
 In the current study we demonstrate that CHD8 interacts with SRF and 
determined the effects of CHD8 on SRF activity in smooth muscle cells.  Results 
from these studies suggest that CHD8 modestly affects expression of SRF-
 55
dependent genes characteristic of differentiation, whereas CHD8 has a more 
significant role in protecting smooth muscle cells from apoptosis.  
 56
C.  Results 
 
 i.  CHD8 is more widely and abundantly expressed than duplin   
 
 From a yeast two-hybrid screen of a mouse intestinal cDNA library 
(Herring et al., 2001) we isolated 2 cDNA clones that encoded the amino terminal 
529 amino acids of CHD8/duplin (Figure 3).  These cDNA were used to rescreen 
lambda gt11 cDNA library made from mouse intestine.  From this screen, 3 
additional cDNAs were isolated.  One of these extended further 3’ and included 
sequence encoding amino acids 282 - 770 of CHD8.  Sequences of these clones 
together with the sequence from image clone #683 (Invitrogen) were used to 
compile the full-length mouse CHD8 sequence. This sequence was found to 
correspond to the previously annotated mouse CHD8 sequence NM_201637.2.  
Duplin, originally discovered in Rattus norvegicus (NM_022933) (Sakamoto et 
al., 2000), and CHD8 are alternatively spliced transcripts of the CHD8 gene.  
Both transcripts are identical in their first 8 exons; however, they diverge in exon 
9 (Figure 2A and B).  CHD8 transcripts utilize an alternative splice donor site in 
exon 9 such that the stop codon encoded by the 3’ portion of exon 9 is removed 
when the alternative donor site is spliced to exon 10.  The most 3’ cDNA that we 
isolated from our mouse intestinal cDNA library includes the exon 9-10 splicing 
pattern characteristic of CHD8 rather than duplin.  
 To further evaluate the expression of duplin and CHD8, RNase protection 
assays (RPA) were performed.  A probe was constructed based on the Mus 
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musculus sequence difference between the isoforms in exon 9 (Figure 2A and 
B).  Results from this anlaysis show that CHD8 is the predominant isoform 
expressed in all mouse tissues and duplin could only be detected at low levels in 
brain (Figure 2C and D).  The apparent lack of CHD8 in rat aortic A10 cells 
reflects species differences in the rat and mouse sequences that prevented its 
detection in this assay, as CHD8 can be readily detected by RT-PCR and 
western blotting in these cells (Figure 3D). As CHD8 is the only isoform detected 
in smooth muscle tissues and a cDNA encoding this isoform was isolated from 
mouse intestine the remainder of the study was focussed on CHD8. 
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Figure 2. CHD8 is more ubiquitously expressed than duplin, its N-terminal splice 
variant.  A. The probe used for RNase protection assays was designed using exons 8 
and 9 of duplin as shown in panel ‘B’. B. Genomic sequence encompassing CHD8 
exons 8-10 as annotated from BLAT on 7-28-08 (only the partial sequence of the 
introns is shown). Exons of full-length CHD8 are shown in bold, exons included in duplin 
are underlined and the shaded region is the probe used for RNase protection assays. 
C. The probe shown in panel A was isolated by RT-PCR from RNA isolated from mouse 
brain. An ethidium bromide stained gel of the RT-PCR products are shown. D. 
Ribonuclease Protection Assays were conducted to determine the amount of full-length 
CHD8 mRNA relative to its splice variant, Duplin in various mouse tissues (left panel) 
and cell lines (right panel).  Cyclophilin was used as an internal control; yeast RNA was 
used as a negative control (Yeast). Abbreviations are as follows:  Sk. Musc. = skeletal 
muscle, Vas Def. = vas deferens, 10T1/2 = 10T1/2 mouse fibroblasts, LI = mouse colon 
smooth muscle cell line , A10 = A10 rat aortic smooth muscle, TTag = T-antigen derived 
colonic tumor cells, 3T3 = NIH 3T3 mouse fibroblasts, MB = myoblast, and MT = 
myotubes. 59
 ii.  CHD8 binds the MADS domain of SRF   
 
 To confirm our yeast two-hybrid result and to map the binding domains of 
SRF and CHD8, GST pull-down assays were performed. (Figure 3A)  Results 
from this analysis demonstrate that CHD8 binds to the MADS domain of SRF, 
and SRF binds to two regions in the N-terminus of CHD8 between amino acid 
residues 282-773 (Figure 3B-C). SRF binds to a region between 282-483 of 
CHD8, and it also binds to the first of the two chromodomains of CHD8 – but this 
binding to the chromodomain is not required for binding to the 282-483 region.  In 
order to confirm that CHD8 and SRF interact with each other within intact cells, 
co-immunoprecipitation (coIP) assays were performed in A10 cells transduced 
with HA-SRF adenovirus.  Western blot analysis revealed that endogenous 
CHD8 co-immunoprecipitated with SRF in these smooth muscle cells (Figure 
3D).  
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Figure 3.  SRF and CHD8 interact both in vitro and in vivo.  A.  Schematic of 
CHD8’s structural domains and truncations used in experiments.  Note that NT-CHD8 
corresponds to the structure of duplin, described in previous sections. B.  GST-WT-
SRF, GST-SRF-∆1, GST-SRF-∆4, GST-SRF-∆5 or GST alone were bound to 
glutathione beads and incubated with NT-CHD8 pET bacterial lysate to determine the 
minimal portion of SRF that binds to CHD8. C. GST-SRF-∆4 was incubated with 
bacterial lysate of various truncations of CHD8.  Following washing the glutathione bead 
bound proteins were analyzed by western blotting. Presence of GST proteins was 
confirmed by ponceau staining.  n = 2  D. Proteins were immunoprecipitated with a 
SRF-specific antibody (Santa Cruz) or an IgG control from nuclear lysates of A10 cells 
that were transduced with HA-SRF AdenoX at an MOI of 100.  Western blot analysis of 
the immunoprecipitated proteins was conducted using the primary antibodies specific 
for CHD8 (Bethyl) and HA-tag (Covance).
 iii.  CHD8 knockdown attenuates expression of SRF-dependent genes in 
smooth muscle cells  
 
 In order to investigate the function of CHD8 in smooth muscle, CHD8 was 
knocked-down in primary mouse smooth muscle cells, using an adenoviral-
encoded shRNA and the subsequent effects on expression of SRF-dependent 
genes were determined by quantitative RT-PCR.  Using this approach we 
obtained an approximately 75% knockdown of CHD8 in primary cells isolated 
from mouse colon, bladder and aorta (Figure 4).  In both bladder and colon 
smooth muscle cells, loss of CHD8 caused a small but significant 10-20% 
attenuation in expression of differentiation genes, such as telokin, smooth 
muscle-MHC, SM22α, calponin, and SM α-actin (colon only) (Figure 4A and B).  
In aortic SMC CHD8 knockdown did not result in any significant changes in the 
expression of smooth muscle-specific genes (Figure 4C).  Expression of SRF 
and cFos were more variable, with neither being changed following CHD8 
knockdown in bladder cells, whereas both were attenuated in aortic cells and 
cFos but not SRF was attenuated in colonic smooth muscle cells.  In addition, 
vinculin expression was significantly attenuated by CHD8 knockdown in each of 
the smooth muscle cell types.   
 Because of the variable affects of CHD8 knockdown on SRF-dependent 
early response genes we further determined whether CHD8 affected the serum 
stimulation of immediate early genes in primary colon smooth muscle cells.  
Knockdown of CHD8 was found not to affect the ability of serum to induce 
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expression of cFos or SRF (Figure 5).  This data suggest that CHD8 is not 
required for serum induction of SRF-dependent growth/proliferation genes in 
colonic smooth muscle cells. 
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Figure 4.  Knockdown of CHD8 causes reduced expression of SRF-dependent 
genes. Passage 1 primary mouse smooth muscle cells were plated at a density of 
5x104 cells per well in 12-well plates.  After 24 hours cells were transduced with an 
adenovirus containing either CHD8-specific shRNA or control shRNA. 72 hours after 
transduction, RNA was isolated using Trizol (Invitrogen). Quantitative RT-PCR was 
conducted using sequence-specific primers for the transcripts indicated A.  In bladder 
SMC, loss of CHD8 affects SM-MHC, SM22α, and vinculin by causing a significant 
decrease in transcript expression.  All data are n = 17, except cFos where n = 13 and 
cMYC where n = 4.  B.  In colon SMC, loss of CHD8 causes a significant decrease in 
SM22α, vinculin, and cFos transcript expression.  All transcripts are n = 14. C.  In aorta 
SMC, loss of CHD8 causes a significant decrease in SRF, cFos and vinculin transcripts.  
All transcripts are n = 4.  For all cell types:  *** p < 0.0001 versus control shRNA, ** p < 
0.001 versus control shRNA and * p < 0.05 versus control shRNA.
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Figure 5.  Knockdown of CHD8 does not affect serum stimulation of immediate 
early or late early genes.  Passage 1 primary mouse colonic smooth muscle cells 
were transduced with an adenovirus containing either CHD8-specific shRNA or control 
shRNA as described in Figure 4.  24 hours after transduction, media was replaced with 
0.5% FBS supplemented DMEM.  Cells were serum starved for 48 hours.  10% FBS 
supplemented DMEM was then given to the cells for 0.5 or 2 hours.  Cells kept in 0.5% 
media were used as controls.  RNA was then isolated using Trizol (Invitrogen) and 
analyzed by quantitative real time RT-PCR.  Results indicate that loss of CHD8 (A) did 
not affect serum stimulation of cFos (B) or SRF (C).  n = 4.  * p < 0.05 versus +shRNA 
control 0.05%.  φ p < 0.05 versus +shRNA control 10% 2hrs. 
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 iv.  CHD8 does not affect induction of smooth muscle markers during 
myofibroblast differentiation   
 
 SRF is important for both smooth muscle and myofibroblast differentiation, 
hence, we next determined if CHD8 is required for myofibroblast differentiation.  
We utilized TGFβ treated 10T1/2 cells as a model for myofibroblast 
differentiation. We found that knockdown of CHD8 in this system did not prevent 
TGFβ-dependent induction of smooth muscle markers such as SM22α and SM 
α-actin (Figure 6).   
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Figure 6.  Loss of CHD8 does not affect TGFβ-dependent stimulation of 
myofibroblast differentiation. 10T1/2 cells were plated at a density of 3 x 105 cells per 
well in a standard 6-well plate.  After an overnight incubation at 37˚C with 5% CO2, cells 
were transduced with adenoviral vectors for shRNA targeting CHD8 as well as an 
shRNA control as described in Figure 4.  However, instead of adding fresh 10% serum 
media after the initial 4-hour incubation, media supplemented with 0.5% FBS was 
added after the virus was aspirated.  24 hours later cells were either given fresh 0.5% 
FBS media containing 1 µl/mL DMSO or TGFβ1 at a final concentration of 2 ng/mL.   
Cells were treated for 24 hours and then RNA extracted for analysis of gene expression 
by quantitative RT-PCR. 
 v.  Loss of CHD8 induces apoptosis in A10 VSMC   
 
 Previous studies have linked SRF to apoptosis through its ability to 
activate the transcription of anti-apoptotic Bcl2 family members.  SRF has been 
shown to be required for differentiation-dependent expression of Bcl-2 through a 
CArG sequence in the Bcl-2 promoter (Schratt et al., 2004).  In addition, Vickers, 
et al., demonstrated that SRF is necessary for Mcl-1 transcription through its 
interaction with the transcription factor Elk-1 (Vickers et al., 2004).  In order to 
determine if CHD8 plays a role in regulating apoptosis in smooth muscle cells we 
knocked down expression of CHD8 or SRF in A10 VSMC and induced apoptosis 
with H2O2.  Analysis of markers of apoptosis such as phospho-H2A.X, caspase-3 
activation and PARP cleavage, in these cells, revealed that knockdown of either 
SRF or CHD8 induced apoptosis in the absence of any additional stimuli (Figure 
7A).  Induction of apoptosis by H2O2 to mimic free radicals created during 
vascular injury further increased the levels of apoptosis in the knockdown cells, 
although H2O2 alone had very little affect in control cells.  Surprisingly, neither 
SRF nor CHD8 depletion appeared to affect the expression of Bcl-2 (Figure 7B).  
While loss of SRF caused a small reduction in Mcl-1 expression, loss of CHD8 
did not significantly affect its expression (Figure 7B).  In addition, even though 
both SRF and CHD8 depletion cause apoptosis-dependent cleavage of Bcl-XL, 
its total expression appears unchanged (Figure 7B).  These data indicate that 
CHD8 plays an anti-apoptotic role in A10 VSMC, but this is not due to its 
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regulation of expression of the known SRF-regulated anti-apoptotic genes in the 
Bcl2 family.  
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Figure 7.  CHD8 imparts a pro-survival effect on A10 vascular smooth muscle 
cells. A10 vascular SMCs were plated at 5x104 cells per well in 12-well plates and 
transduced in quadruplicate with either CHD8 shRNA, SRF shRNA, or control shRNA 
adenovirus as previously described (El-Mounayri et al., 2005; Yin et al., 2006; Zhou and 
Herring, 2005).  After 72 hours, cells were treated with 0.2 mM H2O2 for 6 hours.  Both 
adherent and detached cells were washed twice with PBS, and lysed in 100 µL of RIPA 
lysis buffer. 20 µg of protein from each extract were separated on SDS-PAGE and 
analyzed by western blotting. A.  Loss of CHD8 causes apoptosis as visualized by 
increased expression of apoptotic markers phospho-H2A.X, activated caspase-3 and 
cleaved PARP.  NmMHCIIb and GAPDH serve as loading controls.  Levels of apoptosis 
are similar to those in parallel knockdown of SRF.  B.  Knockdown of SRF appears to 
slightly decrease expression of Mcl-1; whereas, CHD8 knockdown did not consistently 
affect Mcl-1 expression.  
 
 To identify possible targets of CHD8 that could be regulating apoptosis in 
A10 smooth muscle cells we performed a PCR based array screen of 84 
apoptosis related genes (SABiosciences catalog #PARN-012A).  Results from 
this screen revealed a greater than two fold decrease in the expression of 
survivin (Birc5) in CHD8 knockdown cells (Table 1).  These results were 
confirmed using qPCR with primers specific for Birc5/survivin, which also 
indicated a significant decrease in Birc5/survivin expression as a result of CHD8 
knockdown (Figure 8).  These data suggest that CHD8 may be important for 
regulating expression of Birc5/survivin and that attenuated expression of 
Birc5/survivin may be sufficient to induce apoptosis in A10 vascular smooth 
muscle cells. 
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Symbol Name Pro- or anti-apoptotic
Fold Change:  
+shCHD8 v. +control
Aven_predicted
apoptosis, caspase activation 
inhibitor (predicted) Anti 2.75
Birc5
Baculoviral IAP repeat-containing 5, 
survivin Anti -2.2
Card10_predicted
Caspase recruitment domain family, 
member 10 (predicted) Anti -4.67
Casp1 Caspase 1 Pro 3.73
Casp7 Caspase7 Pro -2.63
Il10 Interleukin 10 Pro -2.96
Pycard PYD and CARD domain containing Pro 2.24
Faslg
Fas ligand (TNF superfamily, 
member 6) Pro 3.07
Trp63 Transformation related protein 63 Pro 2.57  
 
Table 1.  Changes in apoptotic genes as a result of loss of CHD8.  The rat apoptosis 
array from SuperArray (SABiosciences catalog #PARN-012A) was used to compare 
CHD8 knockdown to control A10 cells.  Of the 84 key apoptosis genes analyzed on the 
array, those that showed a 2-fold or greater change between control shRNA and CHD8 
shRNA treated cells are shown. A positive number for fold change indicates an up-
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Figure 8.  Loss of CHD8 causes attenuated expression of Birc5/survivin.  A10 
VSMC were plated and infected as described in Figure 7.  qPCR with primers specific 
to Birc5/survivin was conducted in order to confirm a reduction in Birc5/survivin 
expression as a result of CHD8 knockdown in A10 cells; whereas, SRF transcript levels 
remained the same.  n = 8.  *** p < 0.0001 
D.  Discussion 
 
 Previous studies have demonstrated that SRF plays important roles in 
regulating genes required for differentiation, proliferation, migration and 
apoptosis (Chai and Tarnawski, 2002; Hill et al., 1995; Johansen and Prywes, 
1994; Miano et al., 2007; Owens et al., 2004; Pipes et al., 2006; Schratt et al., 
2004; Vickers et al., 2004).  In the current study we found that SRF associates 
with the chromatin remodeling enzyme CHD8 in smooth muscle cells.  CHD8 
appears to moderately affect SRF’s ability to regulate the genes involved in 
smooth muscle differentiation or migration and has no significant affect on the 
serum stimulation of SRF-dependent proliferation genes (Figures 4 and 5).  In 
contrast, knockdown of CHD8 mimics knockdown of SRF in inducing apoptosis in 
smooth muscle cells (Figure 7).   
 Both CHD8 and its alternatively spliced product, duplin have been shown 
to directly interact with the Armadillo repeats of β-catenin in order to negatively 
regulate β-catenin-dependent TCF/LEF transcriptional activation (Sakamoto et 
al., 2000; Thompson et al., 2008).  In the current study, we found that loss of 
CHD8 led to induction of apoptosis in A10 vascular smooth muscle cells.  Even if 
this loss of CHD8 also resulted in de-repression of β-catenin, this could not 
explain the increase in apoptosis, as an active β-catenin signaling pathway is 
characteristic of proliferation and growth, not death.  
 Duplin has also been shown to negatively regulate STAT3 signaling 
(Yamashina et al., 2006). PIAS3, a SUMO E3 ligase that inhibits STAT3 
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signaling, was found to bind duplin.  By binding to STAT3, duplin did not prevent 
STAT3 from translocating to the nucleus, but it was capable of inhibiting LIF-
dependent binding of STAT3 to DNA, which subsequently prevented LIF/STAT3-
dependent transcriptional activation (Yamashina et al., 2006). Even if CHD8 
plays a similar role to duplin in repressing STAT3 signaling it is also unlikely that 
de-repression of this pathway would induce apoptosis. In contrast to duplin’s 
inhibitory role in β-catenin and STAT signaling we found that CHD8 plays a 
positive role in smooth muscle cells. Loss of CHD8 modestly attenuated 
transcription of SRF-dependent target genes involved in differentiation (Figure 
4), indicating that CHD8 would normally function to positively regulate 
transcription of these genes, possibly by aiding in recruiting SRF to DNA through 
CHD8’s chromodomains interacting with histone H3 K4diMe.   
 Previously, CHD8 was shown to interact with the chromatin insulator 
CTCF.  Through this interaction, CHD8 was able to function in the epigenetic 
regulation of the reciprocal transcription of H19 and IGF2, as well as to 
participate in preventing the spread of CpG methylation or condensed chromatin 
adjacent to the BRCA1 and c-myc promoters, respectively (Ishihara et al., 2006). 
The ability of CHD8 to participate in chromatin insulation and preventing the 
spread of CpG methylation may be important for maintaining SRF-dependent 
differentiation genes in an active chromatin confirmation. This could explain why 
CHD8 knockdown attenuates expression of these genes in smooth muscle cells 
(Figure 4).  Alternatively CHD8 could affect expression of differentiation genes 
through its role as an ATP-dependent chromatin remodeling enzyme (Thompson 
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et al., 2008). In support of this proposal CHD8 has been shown to be present in 
complexes that also include the SWI/SNF chromatin remodeling complex 
(Thompson et al., 2008), and we have previously shown that the SWI/SNF 
complex plays a critical role in the induction of smooth muscle differentiation 
genes by the myocardin family of transcription activators (Zhang et al., 2007). 
Additional studies will be required to resolve these possibilities. 
 Loss of CHD8 resulted in a marked increase in apoptosis of A10 vascular 
smooth muscle cells, indicating that CHD8 normally plays an important survival 
function in these cells.  This is consistent with the massive apoptosis that was 
observed in global CHD8 knockout embryos (Nishiyama et al., 2004).  Studies 
have also demonstrated a role of SRF in regulating cell survival as embryonic 
stem cells that are devoid of SRF display increased amounts of apoptosis 
(Schratt et al., 2004).  In this study the pro-survival activity of SRF was 
suggested to result from its ability to regulate differentiation-dependent 
transcription of the anti-apoptotic factor Bcl-2.  SRF has also been shown to 
regulate expression of the anti-apoptotic factor Mcl-1 in both HeLa cells and 
EcR293, transformed human embryonic kidney cells (Vickers et al., 2004).  In 
contrast to these studies, we did not observe any change in expression of Bcl-2 
following knockdown of SRF or CHD8 in A10 vascular smooth muscle cells 
(Figure 7).  Although we did observe a small decrease in Mcl-1 expression 
following SRF knockdown, knockdown of CHD8 did not significantly alter Mcl1 
expression (Figure 7). However, results from a PCR microarray screen revealed 
that knock down of CHD8 significantly attenuated expression of the anti-apoptotic 
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protein survivin (Birc5) (Table 1), which was confirmed with qPCR (Figure 8).  
These data thus suggest that CHD8 may protect vascular smooth muscle cells 
from apoptosis by regulating expression of Birc5/survivin.  Previous studies have 
shown that in a rabbit balloon injury model, Birc5/survivin is up-regulated 4 to 7 
days post-injury in the medial smooth muscle cells, and Birc5/survivin expression 
peaked in the neointima and media at day 14 post-injury (Blanc-Brude et al., 
2002). Importantly, Blanc-Brude, et al., demonstrated that after stimulating 
smooth muscle cells with serum, PDGF-AB or HB-EGF, Birc5/survivin expression 
was increased by 16-fold, 13-fold and 9-fold, respectively, with peak levels 
detected at 20 to 24 hours post-stimulation (Blanc-Brude et al., 2002).  Together 
these data suggest that SRF/CHD8 mediated induction of Birc5/survivin, 
following vascular injury, may help protect medial smooth muscle cells from 
apoptosis. 
 In addition, apoptosis of vascular smooth muscle cells has been shown to 
induce plaque rupture, coagulation, vessel remodeling and calcification (Clarke et 
al., 2008).  Hence the increased expression of survivin in intimal smooth muscle 
cells may play a critical role in promoting plaque stability.  Since SRF plays a 
pleotropic role in pathways that regulate smooth muscle differentiation, migration, 
proliferation and apoptosis it is not an ideal target for therapeutic intervention. In 
contrast, as CHD8 only modest affects transcription of differentiation genes 
whereas it has prominent anti-apoptotic activity, perhaps CHD8 could provide a 
novel target for therapeutic intervention.  
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CHAPTER IV 
Discussion and Future Studies 
 
 Overall, the data presented here indicates that CHD8 plays an important 
role in smooth muscle cell survival, possibly through the regulation of 
Birc5/survivin expression where loss of CHD8 attenuates Birc5/survivin 
expression.  As CHD8 is a chromatin remodeling enzyme (Thompson et al., 
2008) and we have previously shown that Brg1, another chromatin remodeler, 
can regulate SRF through its interaction with MRFTA (Zhang et al., 2007), it is 
credible to believe that CHD8 might also function in similar fashion.  In addition, 
since CHD8 knockout mice are embryonic lethal as a result of massive apoptosis 
and a malfunction during gastrulation (Nishiyama et al., 2004), our results may 
provide important insights into the mechanisms underlying this apoptosis. 
 Several studies have illustrated the importance of apoptosis during 
vascular wall remodeling in multiple cardiovascular diseases (Bennett et al., 
1995; Bochaton-Piallat et al., 1995; Hamet et al., 1995; Korshunov and Berk, 
2008; Lopez-Candales et al., 1997) such as hypertension, restenosis, aneurysms 
and atherosclerosis.  For example, studies demonstrate that compared to 
symptomatic atherosclerotic plaques, asymptomatic plaques have higher 
expression of SM-MHC, but decreased expression of the antiapoptotoic factors 
cIAP2, xIAP and survivin (Korshunov and Berk, 2008; Moran and Agrawal, 
2007).  In addition, increased expression of survivin has been shown to promote 
neointima formation following vascular injury (Blanc-Brude et al., 2002).  
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With regard to the mechanism by which CHD8 regulates apoptosis, we 
currently hypothesize that CHD8 regulates the transcription of SRF-dependent 
pro- or anti-apoptotic genes.  In order to determine whether CHD8 does affect 
the transcription of apoptotic genes, I utilized the rat apoptosis RT2Prolifer™ PCR 
Array from SuperArray (SABiosciences catalog #PARN-012A).  Upon comparing 
samples obtained from A10 cells transduced with shRNA control to shRNA 
specific for CHD8, a total of nine factors out of the 84 tested, were found to 
change by 2-fold or more following knockdown of CHD8.  Genes that were up-
regulated by loss of CHD8 include Aven, caspase-1, Pycard, Fas ligand and 
Trp63 (Table 1).  Genes that were down-regulated after loss of CHD8 include 
Birc5/survivin, Card10, caspase-7 and interleukin-10 (Table 1).  After conducting 
a literature search, Birc5/survivn appears to be the most exciting potential target 
for further examination in that Blanc-Brude, et al., have previously demonstrated 
a role for Birc5/survivin in the regulation of smooth muscle cells during vascular 
injury (Blanc-Brude et al., 2002).  Under basal conditions, Birc5/survivin 
expression is usually low, and Birc5/survivin is only expressed in the G2/M phase 
of the cell cycle in a cycle-regulated manner (Li et al., 1998).  However, using a 
rabbit balloon injury model, studies have illustrated that 4 to 7 days post-injury 
Birc5/survivin is up-regulated in the medial smooth muscle cells, and 
Birc5/survivin expression peaked in the neointima and media at day 14 post-
injury (Blanc-Brude et al., 2002).  In addition, inhibition of survivin was found to 
suppress neointima formation following vascular injury. As our studies suggest 
that CHD8 is required for survivin expression we might predict that conditional 
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smooth muscle-specific CHD8 knockout mice may thus be protected from 
vascular injury.  
Importantly, Blanc-Brude, et al., also demonstrated that after stimulating 
smooth muscle cells with serum, PDGF-AB or HB-EGF, Birc5/survivin expression 
was increased by 16-fold, 13-fold and 9-fold, respectively, with peak levels 
detected at 20 to 24 hours post-stimulation (Blanc-Brude et al., 2002).  The fact 
that Birc5/survivin expression was up-regulated in smooth muscle cells due to 
serum stimulation could provide a link between survivin expression and SRF.  In 
addition, the Blanc-Brude, et al., study illustrated that forced Birc5/survivin 
expression in smooth muscle cells suppressed apoptosis; whereas, inhibition of 
Birc5/survivin by a phosphorylation-defective mutant enhanced apoptosis 
induced by C2 ceramide or TNFα/CHX as visualized by caspase-3 and caspase-
7 activation (Blanc-Brude et al., 2002).  This data could help explain why loss of 
CHD8 in A10 cells caused caspase-3 activation in my current study, as my data 
indicates that loss of CHD8 reduces the levels of Birc5/survivin. 
 To extend and confirm these initial findings, I have designed RT-PCR 
primers for Birc5/survivin and have indeed confirmed that loss of CHD8 in A10 
cells causes a significant decrease in Birc5/survivin expression (Figure 8).  
Additional experiments would need to be conducted to knockdown Birc5/survivin 
in order to determine whether this reduction in expression is sufficient to induce 
apoptosis specifically in A10 cells, though studies by Blanc-Brude, et al., indicate 
that it would be sufficient (Blanc-Brude et al., 2002).  At this time, however, it is 
not clear how CHD8 regulates survivin expression.  Two possible mechanisms 
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can be envisioned, either through direct activation of the promoter via SRF/CHD8 
complexes or perhaps through inhibiting the methylation of the promoter through 
CHD8/CTCF interactions (Figure 9).   
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Figure 9.  Proposed model of CHD8’s regulation of apoptosis through mediation 
of survivin expression.  Two possibilities for CHD8’s regulation of survivin expression 
exist:  (a) by interacting with SRF to mediate transcription up-regulatedd by serum and 
(b) by interacting with CTCF to prevent the spread of CpG methylation. 
 
 Several experiments could be conducted to distinguish between these 
possibilities.  Expression of Birc5/survivin first needs to be examined in A10 cells 
where SRF has been knocked-down to determine if SRF is required to regulate 
survivin expression.  If loss of either SRF or CHD8 causes the same changes in 
survivin transcription, this would support the model in which CHD8 is acting 
through its interaction with SRF.  In addition, in A10 VSMCs serum deprivation-
stimulation assays similar to those conducted in Figure 5 would be utilized under 
parallel CHD8 and SRF knockdown conditions to determine whether loss of 
either CHD8 or SRF prevents the upregulation of Birc5/survivin expression in 
response to serum.  Again, this would help to provide a link between CHD8, SRF 
Birc5/survivin and apoptosis.  Chromatin immunoprecipitation (ChIP) assays 
would be used to determine whether CHD8 and SRF are physically located at the 
Birc5/survivin promoter.  Similarly, in order to elucidate if CHD8 is regulating 
Birc5/survivin expression via interaction with CTCF rather than SRF, ChIP 
assays would also be utilized to illustrate the presence of CTCF and CHD8 at the 
promoter.  Additionally, we would compare the affects of knockdown of CTCF to 
determine if this also affects surviving expression. If CHD8 is regulating 
Birc5/survivin through its interaction with CTCF, then further experiments would 
be required in order to determine if this interaction is functioning to prevent the 
spread of CpG methylation.  To such ends, either bisulfate sequencing or methyl-
sensitive restriction enzyme analysis could be employed in control shRNA versus 
CHD8 shRNA infected A10 cells.  Initially, experiments will focus specifically on 
Birc5/survivin, as it appears to be the most logical target; however, the other 
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genes identified by our array as being affected by loss of CHD8 will also be 
examined in further detail in a similar fashion as described for Birc5/survivin. 
 In addition to playing a role in SMCs, Birc5/survivin has been 
demonstrated to be highly expressed in various forms of cancer.  For instance, 
Kawasaki, et al., found that 53.2% of colorectal tumors expressed high levels of 
Birc5/survivin and correlated with a poor prognosis (Kawasaki et al., 1998).  
Birc5/survivin can inhibit apoptosis by preventing caspase-3 and caspase-7 
activation in the Fas ligand-dependent apoptotic pathway (Asanuma et al., 2004; 
Conway et al., 2002; Tamm et al., 1998).  It would thus be interesting to 
determine whether CHD8 is also highly expressed in colon cancer cells.  If CHD8 
is highly expressed in these cancerous cells, studies could then be conducted to 
knockdown CHD8 in the colon cancer cells to determine if Birc5/survivin 
expression subsequently decreases and allows for the cells to become more 
susceptible to apoptosis.  
 Although I have shown that CHD8 knockdown attenuates survivin 
expression, it is possible that this alone is not sufficient to result in apoptosis. 
Alternatively it is possible that CHD8 knockdown induces apoptosis through 
promoting anoikis (or detachment-mediated apoptosis).  In this model it would be 
predicted that CHD8 is regulating expression of SRF-dependent genes that are 
required for cells to attach to the extracellular matrix.  Likely candidate target 
genes would include the integrins, at least some of which have been previously 
shown to be regulated by SRF, such as alpha-1, alpha-5, alpha-9 and beta-1 
(Miano et al., 2007).  Expression of these integrins would be examined after 
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CHD8 and SRF knockdown in parallel in order to determine if CHD8 is affecting 
their expression.  ChIP assays would determine whether CHD8 is located at the 
promoters of the integrins affected.  Additionally, adhesion experiments would be 
conducted in CHD8 and SRF knockdown cells in the presence and absence of 
zVAD-FMK, a global caspase inhibitor that functions by irreversibly binding to the 
catalytic region of the caspases.  If loss of CHD8 causes apoptosis through 
anoikis, then one would predict that in the zVAD-treated CHD8 or SRF 
knockdown cells, although apoptosis is inhibited, the cells would still detach from 
the cell culture plate in a more significant number than the control cells. 
 As we initially identified CHD8 as an SRF associated protein, our first line 
of thought led us to believe that CHD8 would regulate SRF’s activity in 
proliferation, migration, or differentiation. In contrast to the laboratory’s previous 
dramatic results with loss of the Brg1 ATP-dependent chromatin remodeling 
enzyme, loss of CHD8 caused only a modest attenuation in transcription of SRF-
dependent genes involved in differentiation, and did not affect serum stimulation 
of immediate early genes that are involved in proliferation. A possible explanation 
of these results is that perhaps the remaining amounts of CHD8 in this in vitro 
knockdown model are still capable of allowing for regular function of SRF 
signaling.  Perhaps the effects of the loss of CHD8 would be more dramatic if 
CHD8 was completely ablated.  This could be achieved in an in vivo model, such 
as a smooth muscle-specific conditional CHD8 knockout mouse. To generate 
these mice I would generate a floxed CHD8 allele in which exons 2 and 3 of 
CHD8 are flanked by loxP sites. This would generate a recombined allele in 
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which exon 1 is spliced to exon 4 resulting in incorporation of a stop codon at the 
very beginning of the aberrantly sliced exon 4.  As I have shown that the protein 
product of exon 1 of CHD8 does not bind to SRF or have any other know 
functional domains, then the resulting product of such a recombined allele should 
have no function and will not interfere with normal SRF signaling in cells. In order 
to make the mice conditional and smooth muscle-specific, our lab could use a 
tamoxifen-regulated SM22α-promoter-driven cre mouse line. 
 Another possible explanation as to why loss of CHD8 only modestly 
affected transcription of SRF-dependent differentiation genes is that perhaps 
another member, or members, of the CHD subfamily CHD5-CHD9 could be 
compensating for the function of CHD8.  In order to determine whether this is 
true, it will be first necessary to examine expression of the other CHD proteins in 
A10 cells and smooth muscle tissues.  Specific primers would need to be 
designed to distinguish between each CHD protein, and then mRNA expression 
could be analyzed via quantitative RT-PCR.  Screening could also be conducted 
at the protein level using protein-specific antibodies for each CHD member, 
which would be visualized from nuclear fractions of A10 cells and smooth muscle 
tissue lysates by Western blotting techniques.  Specific smooth muscle tissues of 
interest would include bladder, colon and aorta.  If any of the CHD members 5-9 
are expressed in one or all of these smooth muscle types, the next step would be 
to determine whether SRF forms a complex with any of the members.  To this 
end, coIP assays would need to be conducted similar to those in this study when 
examining CHD8 and SRF interactions.  With each protein found to interact with 
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SRF, subsequent co-knockdown assays would need to be conducted with CHD8.  
To do so, shRNA adenoviral constructs would be cloned from either previously 
published or newly constructed sequences that target each CHD protein.  After 
viral particle packaging and amplification and harvesting, each construct would 
be co-infected with the shRNA specific for CHD8.  In addition, combinations of 
multiple CHD proteins would be conducted if necessary (e.g. CHD8 shRNA + 
CHD7 shRNA + CHD9 shRNA).  Quantitative RT-PCR would be used to examine 
effects of CHD8 knockdown alone versus the combinations on SRF-dependent 
genes.   
 If it is determined that one or more combination causes a more significant 
effect on SRF targets, then ChIP assays will be conducted to examine the 
presence of CHD8 and the newly identified CHD member at the promoters of the 
genes affected. In addition, as CHD8 has been shown to bind to histone H3 
K4diMe and this modification is associated with transcription activation, I would 
also perform ChIP assays to examine the presence of this modified histone at the 
promoters of CHD8 target genes.  Previous data also suggested that CHD8 was 
part of a large complex containing WDR5 and MLL1 (Dou et al., 2005). MLL1 is a 
histone methyltransferase that methylates histone H3 at K4.  It is thus possible 
that this histone modification may not only help recruit CHD8 to the promoters of 
genes but that the CHD8 complex may also promote this activating histone 
modification.  In this latter scenario it would be expected that CHD8 knockdown 
may decrease dimethylated H3 K4 at the promoters of its target genes.  
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 In a separate study CHD8 was shown to be a member of a complex that 
was approximately 900 kD and contained WDR5, β-catenin and but not MLL1 
(Thompson et al., 2008).  This finding together with previous studies showing 
CHD8 as part of a complex with CTCF (Ishihara et al., 2006) and our studies 
showing that CHD8 can be found in a complex with SRF suggest that perhaps 
CHD8 is a member of multiple complexes.  In other words, maybe not all CHD8 
is associated with β-catenin, CTCF, WDR5, MLL1 and SRF in one large 
complex, but perhaps multiple large complexes exist under specific conditions 
and in different cell types. In order to determine whether other factors might be 
part of the CHD8/SRF complex in smooth muscle, coIP assays would be 
conducted to examine the presence of proteins such as CTCF and β-catenin in 
SRF immunoprecipitates.  If another protein is found in the complex, ChIP 
assays could be conducted to determine whether this new protein is also located 
at the promoters of the CHD8/SRF-dependent genes. Luciferase assays could 
also be conducted to examine the effects of this protein on the activation of 
promoters of SRF-dependent genes, alone and in combination with SRF and/or 
CHD8.  In addition, as described above, knockdown and co-knockdown with 
CHD8 could be performed in order to determine the affects of the protein on the 
transcription of SRF-dependent genes.  
 In summary, our current studies identify a novel function for 
chromodomain helicase DNA-binding protein 8 (CHD8) in protecting vascular 
smooth muscle cells from apoptosis.  We have also shown that CHD8 attenuates 
expression of SRF-dependent differentiation genes in smooth muscle cells.  
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Even though we have begun to investigate the mechanism of these functions of 
CHD8, there is still much to be elucidated about the role of CHD8/SRF 
interactions in smooth muscle cells. 
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